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AGONIST-INDUCED CONFORMATIONAL CHANGES IN THE NMDA
RECEPTOR

Ryan James Durham, B.S.

Advisory Professor: Vasanthi Jayaraman, Ph.D.

NMDA receptors are ligand-gated ion channels that mediate a number of
physiological and pathological phenomena within the mammalian central nervous
system. Under the typical course of activation, these receptors bind to glycine and
glutamate molecules and undergo a series of conformational changes that results
in the opening of a cation-permeable pore in the neuronal plasma membrane.
Various aspects of NMDA receptor function are not fully understood, including the
phenomenon of negative cooperativity between the glycine- and glutamatebinding sites of the receptor and the mechanism controlling partial agonism. Past
studies utilizing static structural snapshots of the receptor or isolated domains of
the receptor have provided insufficient insights to fully understand these issues.
Herein, I have conducted Förster Resonance Energy Transfer measurements on
individual NMDA receptor molecules to observe their conformational landscape
under various conditions. These studies have revealed changes in conformation of
the receptor that underlie negative cooperativity and partial agonism, thereby
affording new insights into the mechanisms controlling these processes.
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Chapter 1: Introduction
Utility of Neurotransmitter Receptors in the Process of Neuronal Signaling
During the course of typical neuronal signaling activity in the central
nervous system, neurons must be able to both send and receive signals (1, 2). For
this purpose, neurons that are at rest typically exist in a polarized state where a
negative voltage potential exists between the inside and outside surfaces of the
neuron. This voltage potential enables the neuron to receive input signals in the
form of graded potentials that have the ability to depolarize the neuron and
initiate an action potential. Once an action potential has been initiated, the
resulting electrical signal will pass down the axon of the activated neuron until it
reaches an interface with the next neuron in the signaling pathway known as a
synapse. Here, the signal must be converted from an electrical form into a
chemical form in order to be passed to the receiving neuron.
There are a wide variety of chemicals that are used by neurons to signal
across the synaptic cleft, including glutamate, gamma-aminobutyric acid (GABA),
serotonin, and acetylcholine. Because these chemical molecules transmit signals
between neurons, they are known as neurotransmitters. When the electrical signal
reaches the end of the axon, it causes the signaling neuron to release
neurotransmitters into the synapse. For the signaling to be successful, the
receiving neuron must have the ability to detect the neurotransmitters in the
synaptic cleft. To this end, neurons possess certain molecules on their surfaces that
can detect the presence of neurotransmitters known as neurotransmitter
1

receptors. These neurotransmitter receptors are protein molecules that can detect
a certain neurotransmitter and initiate a response in the downstream neuron,
often in the form of opening an ion-permeable pore in the plasma membrane of
the downstream neuron. This process results in ion flux across the plasma
membrane and therefore converts the signal back to an electrical form.
Neurotransmitter receptors, therefore, play an essential role in communication
between neurons, which controls a large number of physiological processes.

Ionotropic Glutamate Receptors and their Physiological Significance
Certain neurotransmitter/receptor pairs serve to send activating signals to
the downstream neuron, while others send signals that serve to suppress
activation; these signals are known as excitatory or inhibitory signals, respectively
(1, 2). The neurotransmitter that is responsible for the majority of excitatory
neurotransmission in the central nervous system is a molecule known as
glutamate. The neurotransmitter receptors that detect glutamate in the synapse
and mediate the downstream response in the receiving neuron are known as the
ionotropic glutamate receptors (iGluRs). The ionotropic glutamate receptors are a
group of ligand-gated ion channels that are split into three subtypes: the α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, the Kainate
receptor, and the N-methyl-D-aspartate (NMDA) receptor (3). The research
conducted in pursuit of this thesis project concerns the NMDA subtype of iGluR.
All of the iGluRs bind to glutamate on their extracellular side and subsequently
2

open a cation-permeable ion channel in the neuronal membrane (3-5). This, in
turn, creates a graded potential that has the possibility of initiating an action
potential and continuing the signaling process.
The iGluRs play an important role in a number of physiological processes,
including neuronal signaling and development and synaptic plasticity (4, 6), which
underpins the ability to learn and form memories. The iGluRs mediate multiple
different timescales of neuronal signaling, with AMPA and Kainate receptors
activating on the order of tenths of milliseconds to milliseconds and the NMDA
receptors activating more slowly on the order of tens of milliseconds to seconds
(3). NMDA receptors in particular are involved in the phenomenon of synaptic
plasticity, wherein the strength of a synaptic connection changes due to prior
patterns in signaling at that synapse. Synaptic plasticity is thought to underpin the
processes of learning and memory formation at the synaptic level. NMDA
receptors are able to play this role in synaptic plasticity due to their ability to
function as a Hebbian coincidence detector. NMDA receptors require multiple
conditions to be met in order to activate (7). First, depolarization of the plasma
membrane must occur, potentially due to the fast activation of AMPA and/or
Kainate receptors. Prior to depolarization, a magnesium ion blocks the NMDA
receptor ion channel and prevents the flow of ions through the channel.
Depolarization of the plasma membrane results in the alleviation of this voltagedependent magnesium block and causes the ion channel to no longer be prevented
from conducting ions. In addition to having the plasma membrane be
3

depolarized, NMDA receptors also require their respective neurotransmitters to be
present in the synapse in order to activate. When both of these conditions are met,
the NMDA receptor is able to activate and permit ion flux through the plasma
membrane of the neuron. By serving as coincidence detectors, NMDA receptors
serve as a more advanced signaling mechanism to indicate to the neuron that a
change in synaptic strength is necessary.
The calcium permeability of NMDA receptors plays an important role in the
process of synaptic plasticity, whether that be long-term potentiation (LTP) or
long-term depression (LTD). Calcium ions entering the neuron through the
NMDA receptor can bind to and activate kinases that phosphorylate AMPA and/or
Kainate receptors. These phosphorylation events result in altered receptor
properties and/or altered receptor trafficking that can result in a change in the
strength of response at the synapse elicited by future glutamate release into the
synapse. By this process, NMDA receptors mediate synaptic plasticity. There have
been a number of studies that have explored the effect of modulating NMDA
receptor activity on memory formation and learning (8, 9).
In addition to their physiological relevance, NMDA receptors also possess
relevance in relation to various neurological diseases and conditions. Some of the
neurological problems that are associated with NMDA receptor misfunction
include ischemic stroke (10, 11), epilepsy (12), anxiety (13), and schizophrenia (14).
It is therefore clear that NMDA receptors play an important role in a variety of
physiological and disease processes in the central nervous system.
4

Structural Architecture of the NMDA Receptor
Because NMDA receptors play such important physiological and pathogenic
roles in the central nervous system, it is important from both a curiosity-driven
and a therapeutic perspective to gain an understanding of how these receptors
carry out their function and how their function can be modulated.
Macromolecular function is determined first and foremost by molecular
structure; understanding the structure of the NMDA receptor will lead to an
understanding of how the receptor functions. To this end, there have been a
number of studies that have sought to elucidate various aspects of NMDA receptor
structure through various means (15-19). These studies have been largely
successful in determining the overall structure of the ionotropic glutamate
receptors and the NMDA receptor specifically. The ionotropic glutamate receptors
are tetrameric and share a common structural arrangement (16, 20). NMDA
receptors specifically are typically comprised of two GluN1 subunits and two GluN2
subunits that are arranged in an alternating pattern around the central ion channel
pore axis (16, 21) (Figure 1). There are four different GluN2 subunits, GluN2A-D.
The most abundant NMDA receptor subtype in the adult central nervous system
contains the GluN2A subunit, which is the subtype of NMDA receptor that has
been studied in this thesis work (22). Each monomer of the receptor consists of
extracellular amino-terminal and agonist-binding domains, a transmembrane
domain, and an intracellular C-terminal domain. The agonist-binding domains are
5

clamshell-shaped, with two lobes connected by a hinge and a cleft in-between. The
upper, N-terminal lobe is designated the D1 lobe while the lower, C-terminal lobe
is designated the D2 lobe. Additionally, each monomer of the receptor has three
membrane-spanning α-helices, referred to as M1, M3, and M4, and a re-entrant
loop between M1 and M3 referred to as M2. The M2 and M3 transmembrane
segments form the lining of the ion pore. When agonist is present, the agonist will
bind to the cleft between the two lobes of the agonist-binding domain and induce
a closure of the clamshell-shaped domain, as indicated by prior structural studies
(23). This closure motion results in the opening of the ion pore. In the continued
presence of agonist, the receptor will eventually desensitize and adopt an agonistbound, closed-pore conformation.

6
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Figure 1: Structure of the NMDA Receptor
The various subunits of the NMDA receptor are shown with GluN1 subunits
in blue and GluN2A subunits in orange. The domains of each subunit are labeled
on the left, with the intracellular C-Terminal Domain (CTD) not shown. An
expanded view of the GluN1 agonist-binding domain is shown on the right with
the two lobes and agonist-binding cleft labeled. Structure shown is from PDB:
7EOS (24).
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NMDA Receptor Agonists and Inter-subunit Allostery
Although the iGluRs are activated by the neurotransmitter glutamate, the
NMDA receptor is unique amongst the iGluRs in that it also requires a co-agonist
in order to activate (25-27). This co-agonist is typically glycine or D-serine (27, 28).
The different subunits of the NMDA receptor bind to different agonists, with the
GluN1 subunits being the glycine-binding subunits and the GluN2 subunits being
the glutamate-binding subunits (16, 29-31). These ligands bind to the agonistbinding domains of their respective subunits within the NMDA receptor to initiate
receptor activation.
The fact that the NMDA receptor binds to two different agonists during the
course of its activation affords an unique opportunity within the iGluR family to
study the allosteric effects exhibited by one agonist on the other. In some proteins
with multiple ligand binding sites, the binding of ligand to one site affects the ease
of ligand binding to the other sites in a process known as cooperativity. In the case
of the NMDA receptor, the glycine and glutamate binding sites exhibit negative
cooperativity with each other where the binding of ligand to one site causes a
reduction in affinity for ligand at the other site (26, 32).
It has been observed that the NMDA receptor desensitizes after the
application of glutamate and glycine due to a number of different factors. Firstly,
there is calcium-dependent deactivation of the receptor, which results from the
calcium influx through the NMDA receptors activating Calmodulin, which then
binds and deactivates the NMDA receptor (33, 34). Additionally, the NMDA
9

receptor will desensitize in the continued presence of a high concentration of
glycine agonist, which is referred to as glycine-independent desensitization (35,
36). Thirdly, the NMDA receptor exhibits increasing levels of desensitization at low
levels of glycine as the glycine concentration is increased. This desensitization is
referred to as glycine-dependent desensitization, which has been shown to be due
to a reduction in the NMDA receptor’s affinity for glutamate upon binding glycine
(26, 37). It is believed that this phenomenon of negative cooperativity serves as a
way for the activation of the receptor to be fine-tuned. Despite the importance of
this phenomenon within the NMDA receptor and its importance for determining
receptor activation, the structural mechanism by which the agonist binding sites
affect each other allosterically has not been elucidated. This has led to one of the
two specific aims of my thesis work, to characterize the allosteric communication
between the glutamate- and glycine-binding subunits in the NMDA receptor.

Partial Agonism in the NMDA Receptor
In addition to glycine, D-serine, and glutamate, which serve as full agonists
of the NMDA receptor, there also exist a number of partial agonists of the NMDA
receptor (3). A partial agonist is an agonist that will only activate the receptor to a
sub-maximal degree, even when the receptor is exposed to a saturating
concentration of the agonist. One such partial agonist of the NMDA receptor is 1Aminocyclobutanecarboxylic acid (ACBC), which has been found to activate the
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GluN1/GluN2A NMDA receptor to only 13% of the maximal response with glycine
(38).
The structural mechanism underlying partial agonism in the NMDA
receptor is not yet understood. Gaining a greater understanding of how partial
agonists activate the receptor differently than full agonists could yield insights into
the conformational states and changes that control the degree of receptor
activation. For this reason, partial agonists serve as valuable tools for gaining
greater understanding of the structural mechanism of NMDA receptor activation.
There have been prior studies of the mechanism of partial agonism in
iGluRs. Structural studies of the AMPA receptor have shown that full agonists
cause a closure of the clamshell-shaped agonist-binding domain, while partial
agonists cause an intermediate degree of cleft closure (39). This graded cleft
closure is not reflected in the structural studies of NMDA receptors, however, with
partial agonists inducing the same degree of cleft closure in the NMDA receptor as
full agonists (15, 40). It is unknown as to whether this discrepancy is due to
artifacts resulting from the processes involved in obtaining the structures of the
partial-agonist-bound receptors or if a different mechanism is a play in these two
subtypes of iGluRs. In addition to static structural investigations of the mechanism
of partial agonism in the NMDA receptor, studies capable of resolving the dynamic
motions of the agonist-binding domain have been performed. One such study
showed that the ability of an agonist to shift the domain into a closed
conformation correlated with its ability to activate the receptor (41). This study,
11

however, did not take into account the allosteric effects of inter-subunit
interactions as it was performed on the isolated GluN1 agonist-binding domain. A
dynamic study of the partial agonist-bound NMDA receptor in its full-length form
will be necessary to elucidate whether graded cleft closure is present in the NMDA
receptor or if a conformational selection mechanism is at play. Because of this, I
have developed a second specific aim for my thesis work, to determine the
mechanism of partial agonism in the NMDA receptor.

Use of Single-Molecule Förster Resonance Energy Transfer to Study NMDA
Receptors
In order to glean additional insights into the structural mechanisms
underlying negative cooperativity and partial agonism in the NMDA receptor, I
have utilized a technique that is capable of making dynamic measurements of
individual receptor molecules in their full-length form. This technique is known as
single-molecule Förster Resonance Energy Transfer (smFRET). FRET is a process
by which a fluorescent molecule (donor) can transfer energy to another molecule
(acceptor) when those molecules are very close together (on the order of 10-100
angstroms apart) (42, 43). This process relies on overlap between the emission
spectrum of the donor molecule and the excitation spectrum of the acceptor
molecule (Figure 2).
The key factor in FRET that makes it incredibly useful for making
measurements of individual molecules is that the efficiency of energy transfer
12

between the donor and acceptor fluorophores is inversely proportional to the 6th
power of the distance between the fluorophores, making it extremely sensitive to
changes in distance (44). Intuitively, the efficiency of energy transfer increases as
the fluorophores get closer together and decreases as they get farther apart. In this
way, light of a specific wavelength can be used to excite the donor fluorophore,
FRET will occur with an efficiency as determined by the distance between the
fluorophores, and then the acceptor will emit a different, red-shifted wavelength of
light. By comparing the intensities of these different light wavelengths, the FRET
efficiency and the distance between the fluorophores can be calculated (42). For
this reason, FRET is often referred to as a molecular ruler.

13
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Figure 2: FRET Spectral Overlap
The excitation (dotted line) and emission (solid line) spectra are shown for
both donor Alexa 555 fluorophore (green) and acceptor Alexa 647 fluorophore
(red). The yellow region shows the area of spectral overlap necessary for FRET to
occur. This figure was previously published in Litwin, D., Durham, R., and
Jayaraman, V. 2019. Single molecule FRET methods to study Glutamate receptors.
Methods in Molecular Biology 1941: 3-16 (45), and permission to reproduce this
figure has been obtained.
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FRET becomes even more powerful when it is combined with singlemolecule spectroscopy. Using a SiMPull method, it is possible to isolate individual
NMDA receptor molecules on a slide and image them one-by-one to understand
their conformational dynamics (46). In brief, this is achieved by using HEK293
mammalian cells to express NMDA receptors that have been modified to offer sitespecific fluorophore attachment points. These sites are carefully chosen such that
measurements between the sites will report on biologically-significant
conformational changes within the receptor. After the receptor molecules have
been exposed to donor and acceptor fluorescent dyes in order to label the
receptors with the FRET dyes, the receptors are solubilized in detergent solution.
Following a centrifugation step to remove insoluble material, the resulting
supernatant containing fluorescently labeled NMDA receptors is applied to the
smFRET slide. The receptors are attached to the streptavidin-coated slide via a
genetically-encoded Twin-Strep-tag that behaves like biotin. In this way, purified,
immobilized single NMDA receptor molecules that have been labeled with donor
and acceptor fluorophores are prepared for FRET analysis. By exposing each
molecule to donor excitation light and recording the resulting fluorescence from
the donor and acceptor molecules, the FRET efficiency and inter-fluorophore
distance can be measured.
The use of single-molecule FRET has several advantages over ensemble
measurements or static structural analysis methods. First and foremost, the
smFRET technique is powerful due to its ability to observe conformational changes
16

within a single molecule. Ensemble measurement techniques such as
Luminescence Resonance Energy Transfer (LRET) provide only an average of the
entire population (47, 48). In single molecule studies, however, it is possible to
distinctly identify all of the conformational states of a molecule (49). This
capability is useful, for example, in distinguishing between a change in the
conformation of a molecule of interest and a change in the relative occurrence of
two distinct conformational states of that molecule. In an ensemble measurement,
it would not be possible to distinguish between those two possibilities.
Another reason why smFRET is extremely informative for studying protein
dynamics is because it allows for observing transitions between states in real time.
By counting the transitions between the various conformational states, it is
possible to calculate kinetic information about the transitions between states. This
sort of analysis could not be performed when using an ensemble measurement or a
static structural measurement.
An additional reason why smFRET is a useful technique for studying
protein dynamics is that it is possible to confirm that every molecule that is
included in the final data analysis is correctly labeled with one donor fluorophore
and one acceptor fluorophore and that those fluorophores were actively engaging
in FRET during the observation window. To determine the number of fluorophores
of each type attached to each molecule, photobleaching analysis can be utilized
wherein an individual fluorophore will show a sudden and large drop in
fluorescence intensity as it loses its ability to fluoresce (Figure 3). By counting the
17

number of photobleaching steps in each of the donor and acceptor channels for a
given molecule, correct labeling of the molecule can be confirmed. Additionally,
anticorrelation between the donor and acceptor fluorophores upon
photobleaching can be used to ensure that FRET was happening during the
observation of a particular molecule. Assuming that FRET is occurring, the donor
fluorophore is transferring a significant portion (usually over 50%) of its energy to
the acceptor. When the acceptor undergoes photobleaching and decreases its
fluorescent intensity, the energy that it was accepting from the donor is now
instead emitted by the donor as fluorescence. This causes a simultaneous decrease
in acceptor intensity and increase in donor intensity known as anticorrelation. By
ensuring that all molecules exhibited anticorrelation upon acceptor
photobleaching, it can be ensured that all molecules used in the final analysis were
engaging in FRET. For all of these reasons, smFRET has served as a critical tool
that has enabled the study of the dynamic behavior of the NMDA receptor and
given insight into some of the questions about how NMDA receptor activity is
modulated.

18
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Figure 3: Example smFRET Trace
a) A smFRET trace showing the donor (blue) and acceptor (red) intensities
over time. Note that the trace exhibits only a single photobleaching step for each
of the donor and acceptor and also that the donor and acceptor exhibit
anticorrelation at the moment of acceptor photobleaching. b) The resulting FRET
efficiency trace (green) and the same trace after being subjected to a wavelet
denoising process (black) (50, 51). This figure was previously published in
Ramaswamy, S., Cooper, D., Poddar, N., MacLean, D. M., Rambhadran, A., Taylor,
J. N., Uhm, H., Landes, C. F., and Jayaraman, V. 2012. Role of Conformational
Dynamics in α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid (AMPA)
Receptor Partial Agonism. Journal of Biological Chemistry 287(52) 43557-64 (52),
and permission to reuse this figure is not required due to being open access.
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Electrophysiology and Molecular Dynamics Simulations
In addition to single-molecule FRET, electrophysiology and molecular
dynamics (MD) simulations have been employed to gain a greater understanding
of the dynamic behavior of the NMDA receptor (53-55). The work presented in this
thesis has been greatly aided through the use of these techniques by other
members of our lab. In brief, electrophysiology involves attaching a recording
pipette to a single cell or a small patch of cell membrane and measuring ion
channel activity in that cell or membrane patch. This is achieved by locking the
voltage potential across the membrane to a specific value and then observing the
amount of current required to maintain that potential. Ion channel
opening/closing alters this current in a measureable way. This technique has
enabled observation of such things as cooperativity between subunits of the
NMDA receptor and ligand dissociation rates under different conditions (53).
Electrophysiology has also allowed us to confirm that all of the mutations and
modifications performed on the NMDA receptors that were used in these studies
have not disrupted the ability of those NMDA receptors to form functional ion
channels (Figure 18 and Figure 19).
Finally, we have also employed molecular dynamics (MD) simulations in
our studies of NMDA receptor dynamics. MD simulations involve creating a
computer model of a molecule of interest, calculating all of the forces acting on
each piece of the molecule at a given moment, applying a velocity vector and time
step to move the molecule very slightly in response to those forces, and then
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repeating this process many times to obtain a movie of how the molecule moves
around. This technique is very useful as it gives a larger context to the smFRET
measurements by allowing us to view what is happening at every region of the
relevant domains of the receptor. Unfortunately, MD simulations are often
restrained by the amount of computational resources one has access to, so
simulations must be limited in time scale and number of atoms and also typically
do not simulate sub-atomic events such as bond formation or breaking. Despite
these limitations, MD simulations provide a useful tool for observing the general
conformation of a protein domain of interest and complement smFRET
measurements very well by providing a larger context for the single-axis FRET
measurements.
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Chapter 2: Single-Molecule FRET Investigations of Glutamate Signaling
Systems

This chapter is based upon a prior publication: Durham, R. J., Latham, D.
R., Sanabria, H., and Jayaraman, V. 2020. Structural Dynamics of Glutamate
Signaling Systems by smFRET. Biophysical Journal 119(10) 1929-36 (56). This work
has been reproduced here with permission from Biophysical Journal.

Individual author contributions to the above-referenced publication are as
follows: RJD wrote the outline with guidance from HS and VJ, all authors
contributed to writing the manuscript. Express written permission to use this work
in this thesis has been obtained from all co-authors.

Funding for the work presented in this chapter was provided by National
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Introduction
Recent developments in structural biology, mainly through cryogenic
electron microscopy (cryo-EM) techniques, have enabled the study of membrane
proteins and their complexes faster than previously possible through x-ray
crystallography

(57-59).

These

“snapshots”

of

the

proteins

in

multiple

conformations provide a rich background for investigations of the conformational
dynamics necessary to understand the mechanisms mediated by these proteins
through a multitude of biophysical methods. Under these circumstances,
methodologies such as Nuclear Magnetic Resonance (NMR) and Electron
Paramagnetic Resonance (EPR), which provide insights into the conformational
dynamics, are challenged by the requirement of high concentrations of samples
and limitations in protein size. NMR and EPR provide a weighted average of the
heterogeneous population, causing critical information about the individual
dynamics and intermediate configurations to be lost. Single molecule methods
offer a unique solution to ensemble conditions by providing simultaneous
structural and kinetics information from proteins in motion. The ability to observe
protein conformation as a function of time allows for a direct study of the
conformational transitions and kinetics between states (43).
Single molecule Förster Resonance Energy Transfer (smFRET) has become a
mainstream technique for probing biomolecular structural dynamics. As the
number of laboratories using smFRET increases, it becomes imperative to create a
standardized technique to ensure proper usage. Furthermore, it is essential to
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ensure that the proper smFRET experimental design is used to answer the question
of interest. FRET uses the non-radiative transfer of energy from a donor
fluorophore to a nearby acceptor fluorophore to accurately measure the distance
between them (42, 43), because the efficiency of the energy transfer depends on
the inverse distance between fluorophores to the sixth power (44). However,
selecting the appropriate fluorophores and their placement into biomolecules is of
crucial importance. Various types of fluorophores have been employed for singlemolecule FRET including genetically-encoded fluorophores like GFP (60, 61) and
organic fluorophore molecules like the Cyanine dyes (62-64). Additionally,
significant work has been done to develop new fluorophores for use in singlemolecule FRET and to improve the performance of existing fluorophores (64-66).
The most critical criteria to consider when selecting a fluorophore are the R0 factor
of the fluorophore pair, how the fluorophore will be attached to the site of interest
within the protein, and the size of the fluorophore. The R0 factor represents the
distance in Angstroms between two fluorophores at which those fluorophores
experience half maximal energy transfer. Because FRET measurements are most
sensitive to changes in distance when they are close to the R0, the fluorophores
being used should have an R0 value which is close to the distance between the two
sites being measured. Another important factor is the method by which the
fluorophore will be attached to the protein of interest. Strategies for attaching
fluorophores in a site-specific manner are discussed below. Additionally, the size
of the fluorophore is significant as large fluorophores can experience steric
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hindrance with the protein of interest. Steric clashes can alter the conformation of
the protein being studied and can also affect the relative orientation of the
fluorophores, which can cause error in the measurements. Energy transfer depends
upon the alignment of the fluorophores’ dipoles in relation to one another. This
parameter, referred to as the dipolar orientation or κ2, could be estimated by
measuring the fluorescence anisotropy to minimize errors in the determined
distances (67). For best practices, determining the κ2 distribution for each FRET
labeled sample is recommended instead of the assumption of isotropic averaging
leading to the common use of 2/3. Moreover, the use of fluorophores with long
linkers attached to proteins favors isotropic averaging compared to short-linker
fluorophores, which restrict mobility. Therefore, longer linkers lead to small
experimental errors to a maximum of 7%, when considering all uncertainties in the
measurements (68). Energy transfer is only possible when the emission spectrum
of the donor overlaps with the excitation spectrum of the acceptor (42). Once
compatible fluorophores are selected, inter-fluorophore distances from 10 to 136
angstroms with up to 3 angstroms accuracy (68-71) are measurable using mainly
two modalities: ratiometric intensity-based methods or time-resolved fluorescence
(23). By attaching compatible fluorophores to a protein, the distance between two
locations on the protein is measurable at an instant in time. Special care must be
taken to ensure that the incorporation of the fluorophores does not alter the
protein (72, 73). A variety of attachment chemistry exists to link fluorophores to
proteins including click reactions (74), cysteine reactions with electrophiles (75),
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and biorthogonal azide-alkyne chemistry via introduction of unnatural amino
acids (76, 77). Most of the time the selection of the reactive chemistry is imposed
by the wild type sequence of the protein under study. For the purpose of studying
membrane

proteins,

different

treatments

are

compatible

with

smFRET

experiments. Isolated membrane proteins can be solubilized in detergents (53).
Alternatively, incorporating proteins into lipid-containing nanodiscs (78) or
reconstituted vesicles (79, 80) can preserve the physiological lipid context of the
protein. Live cell measurements are also possible (61, 81).
smFRET implementations can be done with freely diffusing molecules or
immobilized molecules on surfaces. Furthermore, data can be collected using
confocal measurements or widefield imaging (Table 1). Selecting the appropriate
combination depends on the question being asked. Typically, with diffusion-based
experiments, confocal measurements are taken. In this case, labeled proteins of
interest diffuse through the well-defined confocal volume of the observing
microscope, and short bursts of photons are observed (82). These types of
experiments are ideal when the dynamic behavior of interest is faster than the
average traversal time through the confocal volume (Figure 4). Furthermore, the
concentration of fluorescently tagged protein within the sample must be low
enough to ensure that only one fluorescent protein is within the confocal volume
at a given time. If a higher protein concentration is required, one could
fluorescently tag a portion of the proteins. This will help ensure only one FRET
pair is present for a given measurement. In the case of immobilized molecules,
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molecules are linked to a coverslip with the most appropriate chemistries. Readers
are encouraged to read (83-85) for more details. When immobilizing molecules,
care must be taken to ensure that the fluorophores do not bind non-specifically to
the protein of interest or to the slide surface (63). Then individual molecules are
located and measured over time using photon-counting detectors via confocal
detection or using cameras (CMOS EMCCDs) via widefield. These experiments are
useful for observing individual molecules over longer temporal timescales.
Photobleaching events are usually tracked to assure only a single molecule is
observed at any given time.
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Confocal
Molecule Freedom Diffusing
Immobilized
Picoseconds to Nanoseconds
Dynamic Ranges
diffusion time to hours
Confocal – Photon counting
Detectors
modules (i.e. PMTs, APDs with
TCSPC)
Limited
diffusion
Number of
through
100 to 500*
molecules
sample volume
– Can be over
100,000
Data Analysis

Trace, Burstwise, BVA,
fluctuation spectroscopy, time
resolved

Widefield
Sub-millisecond to
hours
TIRF (Wide-Field) –
EMCCDs, CMOSs

Limited by molecules
in widefield – ~500

Trace, BVA,
fluctuation
spectroscopy,
camera/image based
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Table 1: Comparison of Confocal and Widefield for Freely-diffusing
Molecules and Immobilized Molecules Measurements
PMT, photon-multiplier tube; APD, avalanche photodiode; TCSPC, timecorrelated single photon counting; BVA, burst variance analysis; TIRF, total
internal reflection fluorescence; EMCCD, electron-multiplying charge-coupled
device; CMOS, complementary metal-oxide-semiconductor. *TCSPC is less
practical in immobilized molecules due to the lower number of sample molecules
which leads to lower photon counting statistics sample size and limits the
minimum dynamic range.
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Figure 4: smFRET Investigations across Different Timescales
Top: The typical time scales for studies of various areas of glutamate
signaling are shown as horizontal bars. The areas of study include both functional
areas (e.g. amino acid transport) and structural areas (e.g. the extracellular domain
(ECD)). ECD, TMD, and IDR refer to the various domains of the ionotropic
glutamate receptors as shown in the inset. smFRET investigations of glutamate
signaling have focused primarily on the second to millisecond timescale, with submillisecond studies lagging behind. Bottom: Various detection and analysis
schemes exist for performing smFRET experiments at a variety of time resolutions.
The ranges of time scales across which the various methods are useful are shown
as horizontal arrows. The time scale of diffusion of free-moving molecules is also
shown as the time scale of the dynamics of interest can determine whether a
diffusion-based or immobilized scheme is more useful for a planned investigation
of single molecule dynamics.
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It is imperative that experiments be designed with the appropriate temporal
scale in mind (Figure 4). There are three significant factors in smFRET
experiments that affect the achievable temporal resolution: protein treatment,
detection mode, and data analysis (43). It has already been mentioned that
proteins can be immobilized or allowed to diffuse freely. After determining which
of these methods works best for making observations at the right time scale for the
dynamics of interest, the proper detector must be selected. It is typical to
immobilize proteins and use a widefield camera when measuring conformational
dynamics that are slower than milliseconds. The photon to electron conversion of
most widefield camera detectors, such as common charge-coupled devices (CCDs),
electron-multiplying

CCDs

(EMCCDs),

and

complementary

metal-oxide

semiconductors (CMOSs), limits the temporal resolution to be around 10s of
milliseconds (Figure 4). This temporal resolution is suitable for measuring larger
domain motion and large-scale conformational rearrangement of proteins (83). By
binning pixels, CMOS cameras can increase their temporal resolution with a time
resolution of up to 250 microseconds being reported (86), but this lowers the
spatial resolution. Photon counting modules like avalanche photodiodes (APDs)
and photon multiplier tubes (PMTs) can be utilized to further increase the
temporal resolution. Temporal resolution is going to be based on the Data
Acquisition system used, i.e., Data Acquisition boards (DAQ) and FieldProgrammable Gate Arrays (FPGAs). Since these modules cannot differentiate
between emission wavelengths, it is crucial to ensure the correct filters are being
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used based on the selected fluorophores. Photon counting allows the
measurement of faster dynamics such as local flexibility and side-chain rotations
with a temporal resolution ranging from 10 microseconds to 100 milliseconds (87).
Including several orthogonal analysis methods increases the extracted dynamics
and the temporal information obtained from smFRET measurements (88-90).
Time-correlated single-photon counting (TCSPC) electronics will measure
fluorescence

and

luminescence

lifetimes

ranging

from

nanoseconds

to

microseconds, respectively (89). Fluorescence correlation spectroscopy (FCS) and
its different variations allow conformational dynamics to be determined over a
broader timescale (91-94).
There exist many different methods for smFRET data analysis, depending
upon the information gathered. Trace analysis is typically modeled with Hidden
Markov modeling (HMM) (95, 96) and many variations (97). Burst-wise analysis,
which looks at the pattern in photon detection to differentiate donor from
acceptor in confocal measurements (98), is often done by probability distribution
analysis (PDA) (99) or burst variance analysis (BVA) (100). The choice of data
analysis depends upon the data collected and experimental design. If FCS and
lifetime information is gathered, this data should be included in data analysis since
it will only help enhance the results. Multiparameter fluorescence detection
(MFD) (23, 101) will ensure the best results are obtained. Many laboratories are
actively developing new software and setting up best practices in terms of data
analysis and offer these packages online for free. These community-based
34

resources range from online software-sharing hubs such as the FRET community
(102) and the kinSoftChallenge (97) to multi-laboratory studies of FRET precision
(68). Given that the size of the protein of interest and the sample concentration are
not limitations for FRET experimental design, smFRET is a versatile methodology
to study membrane proteins and has been used in a wide range of systems such as
G-Protein-Coupled Receptors (GPCRs), transporters, and ion channels. Here we
choose the three systems related to glutamate signaling as an example system
where smFRET methods have provided invaluable biophysical insights.

Glutamate signaling systems studied by smFRET
Glutamatergic signaling is the primary form of excitatory signaling in the
mammalian central nervous system. In this type of signaling, the neurotransmitter
glutamate is released into the synapse where it binds to and activates various
receptor molecules, including ion channels and metabotropic receptors. Following
this glutamate release, the glutamate must undergo reuptake into the presynaptic
neuron and be packaged into neurotransmitter vesicles, a process facilitated by
amino acid transporter molecules (46). Single-molecule FRET studies have been
carried out on proteins from each of these three families of proteins that are
involved in glutamatergic signaling. While the metabotropic and ionotropic
glutamate receptor share some similarities in glutamate binding site, the
transmembrane segments and signaling processes are very different, one being Gprotein coupled and the other an ion channel. The glutamate transport has a
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completely different architecture both at the ligand binding site and in the
transmembrane transporter segments. Thus, while the three systems chosen are
linked by the fact that they are involved in glutamate mediated signaling the wide
range of architectures illustrates the versatility of smFRET as a tool to study the
dynamics and conformations of a wide variety of proteins.
One family of proteins that are involved in the glutamatergic signaling
process are the metabotropic glutamate receptors (mGluRs), which are Class C
GPCRs with large bi-lobed extracellular domains that bind to the agonist
glutamate. Based on end-state structures of agonist and antagonist bound forms of
the extracellular domain, the mechanism for activation by agonists was suggested
to be a closure of the bi-lobed cleft (103-107). smFRET investigations on the
soluble extracellular domain that utilized a diffusing experimental setup with
confocal detection were able to put dynamics into the context of activation and
showed that the domain rapidly fluctuates between the open and closed cleft
states and that the extent of stabilization of the protein in the closed cleft state
dictated the extent of agonism (108) (Figure 5A). While later smFRET
measurements on the full-length receptor that analyzed immobilized molecules
using a TIRF-based detection scheme showed three major states when measuring
across the dimeric extracellular domain at the same sites as in the soluble domain,
agonist efficacy was still shown to be dictated by the occupancy of a closed cleft
state that is consistent with the smFRET studies on the isolated extracellular
domain (109). However, the dwell times for interconversion between the FRET
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states were found to be in the range of tens of milliseconds and not as rapid as
those observed for the isolated extracellular domains. It is possible that the slower
dynamics is due to the stabilization and restricted dynamics of the extracellular
domains in the presence of the transmembrane domains, showing the importance
of investigating the dynamics in the full-length systems.
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Figure 5: smFRET Measurements of Proteins Involved in Glutamate Signaling
The locations of smFRET fluorophore labeling sites and measurements are
shown. These sites are chosen with the goal of studying established (based on
previous structures) or hypothesized conformational changes in these proteins. A)
Measurements performed on the agonist-binding dimer of metabotropic
glutamate receptors (108-111) PDB: 1EWT (105). This measurement site reports on
the conformational changes at the interface between the mGluR dimer, caused due
to the closure of the bi-lobed cleft upon binding agonists. B) Measurements
performed on the trimeric glutamate transporter (112-114) PDB: 1XFH (115). These
measurements report on the distance between adjacent monomers of the
transporter trimer that are expected to monitor motions associated with transport.
C) Measurements performed on an ionotropic glutamate receptor (53) PDB:
6MMK (18). The sites across the agonist binding domain monitor motions across
the bi-lobed cleft caused by agonist or antagonist binding. The sites across the
transmembrane segments are expected to monitor motions across the ion pore.
The side chains of fluorophore-labeled residues are shown as spheres while
distances being investigated are shown as dotted lines.
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smFRET measurements of immobilized molecules were also used to
investigate the role that conformational changes play in determining the
cooperativity between the agonist binding sites in mGluRs (110). These studies
showed that agonist-induced closure of one cleft leads to an allosteric shift in the
dynamic equilibrium of the second unliganded subunit in the dimeric mGluRs.
Thus, the higher spontaneous basal dynamics and closure of the mGluR3
influenced the liganded mGluR2 leading to higher activation in the heteromer.
This mechanism of cooperativity was found to be universal and translated to
mGluR2/mGluR7

heteromers,

highlighting

the

importance

of

such

heteromerization in physiology (111). mGluR7 homodimers have a significantly
lower affinity and activation relative to the other mGluRs. However, in the context
of mGluR2/mGluR7 heteromers, both efficacy and affinity are high. smFRET
studies showed that the heteromeric receptor exhibits faster state-to-state
transitions and therefore has increased conformational dynamics relative to the
homomeric receptor. Additionally, synthetic agonists selective for either mGluR2
or mGluR7 produced a more substantial shift to low FRET (related to higher cleft
closure at the agonist binding domain) than observed when both subunits were
bound in the corresponding homomeric receptor, correlating well to a stronger
activation. These experiments that allow for studying individual heteromeric
combinations are possible as specific combinations can be pulled-down onto the
slides used for smFRET imaging (46, 53, 63). This selective pull-down of
heteromeric receptors is achieved by placing the fluorophore labeling sites on one
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subunit and placing the affinity tag for attachment to the slide on the other
subunit. Using this strategy, molecules that do not contain a subunit with the
affinity tag will not attach to the slide, and molecules that do not contain any
fluorophore labeling sites will not be observed. This ensures that immobilized
molecules that exhibit a FRET signal contain at least one of each of these two
subunits.
Glutamate transporters catalyze neurotransmitter uptake from the synaptic
cleft into the cytoplasm of glial cells and neurons. The bacterial homolog of the
glutamate

transporter,

the

sodium/aspartate

symporter

from

Pyrococcus

horikoshii, GltpH, has served as a model system for studying structure-function
correlations in this family. The initial framework provided by the X-ray structures
of the protein in several conformations along with the slow turnover rate of tens of
seconds for this protein made it ideal for direct structure-function studies using
tethered smFRET (112, 113, 115, 116) (Figure 5B). These studies provided direct
evidence for “elevator-like’ motions for transport and also showed that each
subunit could undergo motions independent of each other (79, 113, 114). This
motion also has a burst-like pattern with periods of quiescence and periods of
rapid transitions (79). The rapid dynamic mode was hypothesized to be due to the
separation of the transport domain from the trimeric scaffold allowing for the
rapid domain movements across the bilayer. Two mutations introduced into GltpH,
for imparting characteristics of the human glutamate transporter, lead to increased
transport domain dynamics. The increased dynamics correlated to the increased
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rate of substrate transport observed in the human glutamate transporters relative
to GltpH, providing a direct temporal relationship between transport domain
motion and substrate uptake (114). Several of these investigations were performed
in proteoliposomes, with the transporter tethered on the slide. Tethering allows
for a specific outside-out orientation of the transporter, making it possible to tune
the concentration of luminal and external ions and substrates, leading to more
physiologically relevant studies.
An additional class of membrane proteins that are investigated through
smFRET is ion channels. Extensive smFRET investigations have been carried out
on members of the ionotropic glutamate receptors (iGluRs). Initial studies were
performed on the soluble agonist binding domain of the receptor, in particular the
AMPA subtype of the iGluRs. X-ray structures of the isolated agonist binding
domain showed a correlation between the extent of cleft closure at the bi-lobed
agonist binding domain and the extent of activation in several cases (117-122).
However, this relationship broke down in mutants, such as the T686S, where the
cleft showed full closure even when the extent of activation was only partial (123).
smFRET measurements that utilized immobilized protein molecules on a surface
probed all the states that the protein occupies and reconciled this issue by showing
that the mutant protein occupied a wide range of conformations and that the
activation is dictated by the fractional occupancy of the high FRET closed cleft
agonist binding state (52, 124). More importantly the smFRET studies also showed
that the distance changes between the most probable states for the different
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liganded conditions and the mutant correlated with the X-ray structures showing
that distance changes can be accurately measured by smFRET.
Similarly, cryo-EM structures of full-length AMPA receptors showed
varying degrees of decoupling across the dimers within the tetrameric aminoterminal domain of the receptor that is associated with receptor desensitization.
Hence, the role of this decoupling in desensitization was debated (125-127). The
complete conformational landscape that could be probed with smFRET at this site
using the immobilized full-length receptor showed that largely decoupled states
did exist under desensitizing conditions. However, a larger fraction of the receptor
showed smaller decoupling, this large decoupling is not required for
desensitization (128). Additionally, based on the distances we could directly relate
the conformations observed in the smFRET data to specific cryo-EM structures
(128). Recently smFRET investigations were used to study the mechanism of
cooperativity between the agonists glutamate and glycine in the NMDA receptor
subtype of the iGluRs (53) (Figure 5C). The smFRET investigations of immobilized
receptors showed that the binding of one agonist causes a stabilization of the
closed cleft bi-lobed agonist binding domain and lower conformational
fluctuations at the site where the agonist binds, but an increase in conformational
flexibility and dynamics at the second agonist site. The loss of such an effect in a
mutant receptor where such negative cooperativity was not observed (32)
confirmed that certain conformational states observed via smFRET at the second
agonist binding site contribute to the lower affinity of the second agonist when the
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first agonist is bound to the receptor. These studies again highlight the importance
of conformational dynamics in function, along with the need to understand the
complete conformational landscape of the receptor that is possible through single
molecule methods.
smFRET also stands to contribute significantly to our understanding of
macromolecular dynamics for intrinsically disordered proteins (IDPs) or
intrinsically disordered regions (IDRs). The inherently dynamic nature of IDPs is
incompatible with analysis for static structure through cryo-EM or X-ray
crystallography, either because the study is unsuited for analyzing a molecule with
little structure or because the results fail to capture a complete understanding of
the dynamics of the protein. However, smFRET can report on the conformation of
a protein over time without averaging over an ensemble. Combining static
measurements and smFRET allows the gathering of valuable information
concerning IDPs or IDRs (129, 130). For example, from studies of both diffusing
and immobilized proteins, it was determined that the IDR C-terminal domain
(CTD) of the GluN2B subunit is required for GluN2B to regulate NMDARs (108,
111, 131-133). The use of smFRET has helped to understand the role of
posttranslational modifications on the ionotropic glutamate receptors’ disordered
intracellular segments (134-136). Bowen and Choi used smFRET measurements of
immobilized molecules to show differences in conformational dynamics as well as
changes in the extent of disorder due to phosphorylation (134, 137). Given that
there is little structural insight for this segment of the protein, these early studies
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pave the way for future investigations into how disorder and dynamics in these
segments modulate receptor function.

Perspective
To observe several essential conformations for mediating functions of
glutamate singling systems, smFRET must be used. This allows for determining the
complete conformational landscape and dynamics that are not observed using only
structural methods, such as cryo-EM and X-ray crystallography. smFRET also
highlights the dynamic nature of these systems and the role of such dynamics in
function. The smFRET technique’s versatility in terms of the ability to probe
protein complexes of all sizes with minimal requirements in terms of
concentration and in a near-native state allows for similar investigations on the
large number of membrane proteins for which end-state structures are available
through cryo-EM. Moreover, with the ability to measure FRET with high precision,
it is now possible to use FRET-derived distances in combination with other
structural biology tools or molecular dynamics (MD) simulations to model protein
structures (138, 139) and deposit them in pdb-dev (140). Static structures enable
the rational design of starting points for MD simulations and the selection of
fluorophore attachment points for smFRET measurements. MD simulations show
dynamic motions not revealed with static structures alone and reveal the regions
of a molecule that will show biologically relevant motions that can be measured
with smFRET. smFRET measurements can provide constraints for MD simulations
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that enhance the physiological relevance of simulation results and provide insight
into highly dynamic regions of proteins that cannot be well resolved through static
structural methods alone. However, it is important to understand all the physical
aspects and parameters of the dye to obtain accurate simulations. As machine
learning continues to advance, it will become a great tool for smFRET data analysis
(141, 142).
Furthermore, the field of correlative microscopy is yet to expand on the
possibility of combining FRET and CryoEM. In this way, structural biology
techniques, molecular dynamics simulations, and smFRET measurements can be
combined to provide a greater understanding of various biological systems on the
single molecule level. The development of detectors and data analysis methods
that function at sub-millisecond time resolutions has enabled the investigation of
new research questions relating to the structure and dynamics of individual
molecules. However, the studies that utilize smFRET have focused primarily on
the timescale of seconds to milliseconds, with sub-millisecond studies lagging
(Figure 4). The future of the smFRET field will involve expanding investigations
into the sub-millisecond dynamics of individual molecules. As the tools and
methods needed to investigate sub-millisecond dynamics become more widely
available, with data analysis methods becoming increasingly standardized, the area
of sub-millisecond dynamics will continue to expand and answer as-yetunresolved research questions.
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Chapter 3: Studies of the Mechanism of Inter-Subunit Negative
Cooperativity in the NMDA Receptor

This chapter is based upon a prior publication: Durham, R.J., Paudyal, N.,
Carrillo, E., Bhatia, N. K., Maclean, D. M., Berka, V., Dolino, D. M., Gorfe, A. A.,
and Jayaraman, V. 2020. Conformational spread and dynamics in allostery of
NMDA receptors. PNAS 117(7) 3839-47 (53). This work has been reproduced here
with permission from PNAS.

Individual author contributions to the above-referenced publication are as
follows: R.J.D. purified the receptors, performed the smFRET measurements,
analyzed the data, and wrote the manuscript. N.P. performed the computational
simulations, analyzed simulation results, and wrote the manuscript. E.C.
characterized the mutations and performed the BZP-crosslinked negative
cooperativity electrophysiology. D.M.M. performed the negative cooperativity
electrophysiology. V.B. collected and analyzed the smFRET data. D.M.D. made the
mutations. N.K.B. made the mutations and performed the western blotting. A.A.G.
designed the MD simulations, interpreted the simulations, and wrote the
manuscript. V.J. designed the research, interpreted the results, and wrote the
manuscript, Express written permission to use this work in this thesis has been
obtained from all co-authors.
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Introduction:
Allostery is a mechanism through which proteins are able to tune their
function in response to events such as binding of ligands at regulatory sites. Initial
mechanisms of allostery were based on limited conformational states of the
protein leading to the classic two state and sequential models (143, 144). Given our
current understanding that proteins are dynamic entities sampling an ensemble of
conformations, it has become evident that the mechanism underlying allostery is
based on changes in the free energy landscape brought about by a combination of
changes in conformational selection and dynamics of the protein (145, 146). The
measurements of conformational landscapes and dynamics have been largely
limited to smaller soluble proteins due to the difficulty in using typical methods
such as NMR and molecular dynamics simulations to study more complex and
larger proteins such as channels, receptors, and transporters. Recent advances in
single molecule fluorescence resonance energy transfer (smFRET)-based methods
open the door for investigations of the dynamics and conformational landscape in
larger multidomain membrane proteins (63, 109, 147), thus allowing for an
understanding of allostery in these proteins in terms of these parameters.
The N-methyl-D-aspartate (NMDA) receptor is an ideal candidate for such a
study, as the allosteric mechanism underlying the functionally-well-characterized
negative cooperativity between agonist binding sites, as well as activation and
desensitization of the transmembrane segments, is still limited to our knowledge
of the end state static structures. NMDA receptors are one of three subtypes of
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ionotropic glutamate receptors, which are cation-permeable ligand-gated ion
channels (3-5). Glutamatergic signaling mediated by ionotropic glutamate
receptors accounts for the majority of excitatory neurotransmission in the
mammalian central nervous system. NMDA receptors in particular are crucial in
the processes of synaptic plasticity, learning, and memory formation, as evidenced
by the altered learning behavior exhibited by animals with altered NMDA receptor
function and expression (8, 9). Additionally, NMDA receptors are implicated in a
number of neurological disorders and diseases including ischemic stroke and
epilepsy (4).
NMDA receptors are unique among the closely related glutamate receptor
family members in being obligate heterotetramers consisting of glycine-binding
GluN1 and glutamate-binding GluN2 subunits (16, 29-31). Hence, the binding of
both glycine and glutamate is required for receptor activation and the formation of
cation-selective transmembrane channels. Endogenous glycine was initially
thought to potentiate neuronal NMDA receptor currents (25) but was later
established to be required for NMDA receptor activity (27). Some of the
complicating factors in understanding glycine’s role in NMDA receptor activation
have been its high affinity to the receptor and its negative cooperativity with
glutamate, which was observed as “glycine-dependent desensitization”. This
phenomenon, seen as an increase in “desensitization” at sub-saturating
concentrations of glycine, is actually deactivation that arises due to the receptor’s
affinity for glycine being lowered upon binding glutamate (37). This causes the
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initial glycine-glutamate-mediated peak current to decrease as glycine molecules
dissociate from the receptor. While negative cooperativity between glutamate and
glycine has been previously established through these functional measurements
(32, 148, 149), the allosteric mechanism underlying the combination of repression
in binding between the two agonists and activation of the receptor upon binding
both agonists is largely unknown.
The structure of the NMDA receptor in the antagonist- and glycineglutamate-bound states is known (16, 29, 30). NMDA receptors are modular with
each subunit having distinct domains, an amino-terminal domain, an agonistbinding domain, transmembrane segments, and an intracellular C-terminus. The
structures, along with spectroscopic studies (63, 150, 151) and computational
simulations (152, 153), show that the bi-lobed agonist-binding domain undergoes
cleft closure upon binding agonists. The current view of activation in this receptor
is hence primarily limited to these end state structures and the allosteric
mechanism for activation is proposed in terms of a rigid body cleft closure
conformational change being propagated to the transmembrane segments leading
to receptor activation and subsequent desensitization. These structures also show
two interfaces that play important roles in receptor activity (154), inhibition (18),
as well as deactivation rates of agonists (155). There are currently no structures of
the receptor in the presence of single agonist, hence there is currently no
mechanism known, even in terms of end states, for negative cooperativity between
the agonists.
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Here to address the question of allostery and negative cooperativity, we
have studied the conformational landscape by measuring the distance across the
bi-lobed agonist binding clefts as well as across the transmembrane segments
using smFRET. These studies are complemented with molecular dynamics (MD)
simulations of the extracellular portions of one glycine-binding GluN1 and one
glutamate-binding GluN2 subunit. This portion of the receptor was chosen as the
minimal unit for the MD simulations due to the fact that the amino-terminal
domain and agonist-binding domain of the glutamate-binding GluN2 subunit
exhibit extensive interactions with the glycine-binding GluN1 agonist-binding
domain. MD simulations of the ABD dimer were also performed to understand the
contribution of the intra-dimer interface to the negative cooperativity. The
combined smFRET and MD simulations are able to provide insight into the
mechanism of allostery for both negative cooperativity and activation in terms of
conformational fluctuations and conformational selection in this protein.

Results:
Negative cooperativity between glycine and glutamate. We estimated the
rate of glycine dissociation in the absence of glutamate and the deactivation in the
presence of glutamate by using a fast piezo-driven triple jump method on outsideout patches of HEK-293T cells expressing wild type GluN1/GluN2A receptors. To
study the deactivation of glycine in the presence of glutamate, channels were preincubated with glycine (100 µM) and then jumped into both glycine (1 mM) and
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glutamate (1 mM) solution for 2-5 ms to activate the receptors before a final jump
into 5-methyl-indole 2-carboxylic acid (MeICA, 10 mM) and glutamate (1 mM)
(Figure 6a). MeICA is a low affinity glycine site antagonist which prevents
contaminating glycine from rebinding during this wash phase but falls off
sufficiently quickly to enable rapid activation of NMDA receptors (156). To study
the dissociation of glycine in the absence of glutamate, the receptors were preequilibrated with glycine (100 µM) and then jumped into a ‘no agonist’ solution
(containing MeICA, 10 mM) for variable times before a test pulse of saturating (1
mM) glutamate to probe the active fraction of channels, i.e. channels still bound to
glycine (Figure 6b). Using these protocols we found that the dissociation of glycine
in the absence of glutamate occurred with a weighted time constant of 400 ± 50 ms
(n = 5) while the deactivation in response to glycine removal in the presence of
glutamate occurred with a weighted time constant of 119 ± 7 ms (n = 7, Figure 6c),
more than 3 times faster. Complementary experiments performed to measure the
dissociation of glutamate in the presence and absence of glycine (Figure 6d-f),
showed that glycine similarly increases the rate of dissociation of glutamate from
90 ± 5 ms (n=5) to 50 ± 7 ms (n=5), making it 1.8 times faster. These experiments
establish the negative cooperativity between the ligands.
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Figure 6: Responses from Outside-out Patches Expressing GluN1/GluN2A Subunits
(A) Patch was equilibrated in glycine (100 μM) and jumped into glycine plus
glutamate (1 mM) for 4 ms followed by glutamate and the low-affinity GluN1
competitive antagonist MeICA (10 mM) to measure receptor deactivation time
course upon glycine removal in the presence of glutamate. (B) Patches were
equilibrated with glycine before jumps of variable time into control solution with
MeICA to allow for glycine dissociation followed by test pulses with glutamate. (C)
Summary across 5 to 7 patches from experiments in A and B. (D–F)
Complementary experiments with the roles of glycine and glutamate reversed in
order to measure receptor deactivation upon glutamate removal in the presence
and absence of glycine.
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Conformational landscape of the agonist-binding domain. In order to
measure conformational changes across the cleft of the glycine-binding bi-lobed
GluN1 agonist-binding domain we introduced cysteines at sites T701 and S507 on a
cys-light background GluN1 construct (Figure 7) (GluN1*-ABD), and coexpressed it
with a cys-light glutamate-binding GluN2A (GluN2A*). To measure the changes
across the cleft of the glutamate-binding GluN2 agonist-binding domain we
introduced cysteines at site Q503 and M701 on GluN2A* (GluN2*-ABD) and this
was coexpressed with GluN1*. The functionality of the receptors was verified using
electrophysiology (Figure 18), and glutamate dose-response curves were measured
for the receptors to ensure that their glutamate sensitivity was not significantly
different from that of wild type receptors. In the case of GluN1*-ABD, to ensure no
cross talk across two GluN1 subunits, we co-expressed GluN1*-streptag, GluN1*ABD, and GluN2A* subunits in HEK-293T cells, labeled them with donor and
acceptor fluorophores (Alexa 555 and Alexa 647), and used in situ streptavidin pull
down to attach the detergent-solubilized receptor to the streptavidin-coated cover
slip (Figure 7). This ensured only one GluN1*-ABD per receptor. GluN2*-ABD sites
are such that the distances are outside significant FRET across the subunits and
hence do not require this additional step. The distances within one ABD are
between 33-40Å which would yield FRET signal of 81-93%, while the shortest
distance between two fluorophore attachment sites that are not on the same ABD
is 65Å, which would yield a FRET signal below 20% which is easily separated from
the FRET signal of interest (18). To ensure a single FRET distance was being
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measured, only traces showing a single donor and single acceptor photobleaching
step with anticorrelation were used. Efficiency traces from at least 30 molecules
were used to generate ensemble-averaged FRET efficiency histograms for the
GluN1 and GluN2A agonist-binding domain under conditions of apo, glycine
bound, glutamate bound, and glutamate-glycine bound (Figure 8). Wavelet-based
denoising along with Step Transition and State Identification (STaSI) analysis was
used to determine the states of the receptors within the averaged FRET histogram
(41, 49). Additionally, the raw observed histograms that had not been subjected to
denoising were fit to a series of Gaussian curves, and the two methods of analysis
show similar states ensuring no bias from the type of analysis.
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Figure 7: Fluorescent Labeling Strategy for GluN1-ABD Measurements
GluN1*-ABD (green, Left), GluN1*-streptag (green, Middle), and GluN2A*
(cyan, Right) constructs were transfected into HEK 293T cells to yield the three
possible subunit combinations shown on the right. Cysteines for the attachment of
fluorophores are shown in red, native cysteines that were mutated to serines to
prevent off-target labeling are shown in yellow, and the Twin-Strep tags used to
attach the receptors to the coverslip are shown in orange. Receptors require at
least one pair of fluorophores to yield a FRET signal and at least one Twin-Strep
tag to attach to the coverslip; only the receptors that have both will be observed
during the experiment. Structures are based on PDB: 6MMG (28).

59

60

Figure 8: Measurements of the Agonist-Binding Domains
smFRET histograms (A–D) and state transition probability maps (E–H) for
the (I) glycine-binding domain and (II) glutamate-binding domain of the NMDA
receptor. smFRET data of the GluN1*-ABD/GluN2A* receptor or the GluN1*streptag/GluN2A*-ABD receptor was used to generate smFRET efficiency
histograms. The observed histograms are shown in gray and the denoised
histograms are shown in color. Individual states identified by STaSI analysis are
labeled according to their efficiencies. The observed histograms were fit to
Gaussian curves, and the cumulative Gaussian fit is shown as a gray curve.
Additionally, the state transition probability maps for each condition are shown. A
total of 1 mM glutamate and/or glycine was used as needed for the various
conditions studied. Conditions shown in I are apo (A and E), glycine-bound (B and
F), glutamate-bound (C and G), and glutamate-glycine-bound (D and H).
Conditions shown in panel II are apo (A and E), glutamate-bound (B and F),
glycine-bound (C and G), and glutamate-glycine-bound (D and H).
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Direct effect of agonist binding on the agonist-binding domain. The smFRET
histograms for both the glycine- and glutamate- binding domains show a shift
from lower to higher FRET efficiency upon agonist binding to the domain being
probed (Figure 8). The distance of 42Å for the primary FRET efficiency state of
0.76 ± 0.01, under apo conditions in the glycine-binding domain is similar to the
distance of 40 Å observed in the X-ray structure of the antagonist bound form of
this domain (157). The distance of 30 Å for the highest occupancy FRET state which
has an FRET efficiency of 0.94 ± 0.05 in the glycine bound state, is similar to 33-34 Å
distances observed in the glycine bound structures (157). The distance of 39Å for
the primary FRET efficiency state of 0.83 ± 0.01, under apo conditions in the
glutamate binding domain is similar to the distance of 39 Å observed in the X-ray
structure of the antagonist bound form of this domain (157). The distance of 34 Å
for the primary FRET efficiency state of 0.92 ± 0.01 in the glutamate bound state is
similar to the distance of 36 Å observed in the glutamate bound structures (157).
The shift to higher FRET efficiency states indicates a shift towards shorter
distances, which in turn is consistent with the prior structures and spectroscopic
investigations which show a cleft closure upon binding agonists (16, 29, 30, 63, 150,
151, 158). In addition to the shift in the population, the smFRET data also shows
the existence of both high and low FRET states in both the apo and agonist-bound
forms, albeit with differing fractions, providing direct evidence for a shift in
conformation upon agonist binding towards pre-existing states, which indicates a
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conformational selection model for agonist binding at both the glycine and
glutamate site of the receptor.
To study conformational dynamics, the transition probabilities between the
states were determined. The transition probability is calculated based on the
number of transitions observed in the smFRET data taking into account the
relative occurrence of the starting state from the smFRET traces. The transition
probability maps for each measurement site were also normalized to the maximum
probability observed for a given site thus allowing for comparison between
different liganded conditions at a given site as well as across different sites. The
normalized state transition probability maps reveal that the probabilities for the
state transitions are significantly higher in the apo state (Figure 8 Ie and 8 IIe)
compared to when the domain has an agonist bound to it (Figure 8 If and 8 IIf),
showing that the conformational fluctuations are lowered when the domain is
bound to an agonist.
Allosteric effect of second agonist on the first agonist-binding domain. The
smFRET histogram for the glycine-binding domain in the presence of glutamate
alone has a broad spread of FRET efficiencies (Figure 8 Ic). This condition shows
population of states that are both lower and higher FRET than those observed in
the apo state. This suggests that glutamate binding to the GluN2 subunit
destabilizes the GluN1 glycine-binding cleft with larger conformational
fluctuations. Similarly, the smFRET histogram for the glycine-binding domain in
the presence of both glutamate and glycine again favors the lower 0.84 FRET
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efficiency (Figure 8 Id) state relative to what is observed in glycine alone,
suggesting that the slightly more open cleft is favored in the presence of glutamate
relative to its absence even when glycine is bound. In addition to the
conformational spread, the transition probabilities between states at the glycinebinding domain are significantly larger when only glutamate is bound to the
receptor relative to those under apo conditions (Figure 8 Ig versus Figure 8 Ie) and
are slightly higher in the glutamate-glycine-bound state relative to the glycinealone-bound state (Figure 8 Ih versus Figure 8 If). These results show that
conformational spread favors more open cleft states and that the higher
fluctuations in the conformational states allow for the receptor to transition into
these open cleft states more often, these in turn are expected to favor glycine
dissociation and disfavor glycine binding, thus leading to the lower affinity for
glycine in the presence of glutamate.
The conformational spread at the glutamate agonist-binding site shows
similar shifts as observed at the glycine agonist-binding domain. The smFRET
histograms show a slight shift in population towards lower efficiencies due to the
presence of glycine in both the apo state (Figure 8 IIa and 8 IIc), and the
glutamate-bound state (Figure 8 IIb and 8 IId). The state transition probability
maps show significantly larger dynamics in the glycine-alone-bound state,
specifically in the transitions populating the lower FRET efficiency open cleft
states (Figure 8 IIe-h). Both the shift towards lower efficiency states as well as the
high probability of transitions to and from these states would contribute towards
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dissociation of glutamate in the presence of glycine. The differences are not as
large as those observed at the glycine-binding site, which is consistent with the
fact that the co-agonist-induced changes in glutamate dissociation rates are
smaller (1.8 times) relative to the changes in glycine dissociation (3 times).
Role of agonist-binding domain interfaces in mediating negative
cooperativity. The GluN1-GluN2 agonist-binding domains have two major
interfaces, which are shown in Figure 9 Ia (interface I) and Figure 9 IIa (interface
II). To determine the role of specific interfaces in the changes in the cleft of the
individual domains and their possible role in negative cooperativity, we performed
molecular dynamics simulations using minimal constructs that maintained the
interfaces of interest (Figure 9 Ia and Figure 9 IIa). To examine the cleft
opening/closing dynamics, the distance histograms between the Cα atoms of T701
and S507 of the glycine-binding cleft and Q503 and M701 of the glutamate-binding
cleft (which are the sites used for smFRET measurements and are shown in Figure
9 Ia and 9 IIa) were determined from the simulations after the protein was
equilibrated (Figure 9 Ib-c Figure 9 IIb-c). The glycine-binding cleft for the
minimal model with interface I (Figure 9 Ib) shows the glycine-alone bound state
to be the most closed, followed by glutamate-glycine-bound, apo, and glutamatebound in that order. Similarly for the glutamate cleft for the minimal model with
interface I (Figure 9 Ic) the most closed state is when glutamate is bound, followed
by glutamate-glycine-bound, apo, and glycine-bound in that order. The trends
observed in the MD simulations, particularly with respect to the cleft opening
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more in the second agonist-binding site when agonist is bound to the first site, are
similar to what is observed in the experimental smFRET measurements.
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Figure 9: Molecular Dynamics Measurements of the Agonist-Binding Domains of
the NMDA Receptor
(IA and IIA) The minimal constructs used for the simulations with GluN1
(tan), GluN2A (blue), and the residues for measuring cross-cleft distances (red and
blue spheres). (IB and IIB) MD measurements of the glycine-binding GluN1 cleft.
The distance between Cα atoms of residues Ser-507 and Thr-701 was measured. (IC
and IIC) MD measurements of the glutamate-binding GluN2A cleft. The distance
between Cα atoms of residues Gln-503 and Met-701 was measured.
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The cleft histograms for simulations with the minimal model for interface II
(Figure 9 II) show no changes in the degree of cleft closure at the glycine-binding
domain between the glycine-alone and glutamate-glycine bound states (Figure 9
IIb). The only effect seen is a shift towards a slightly more closed state at the
glycine cleft when glutamate alone is bound relative to the apo state. At the cleft of
the glutamate-binding domain (Figure 9 IIc) the cleft is open and similar in the
case of glycine alone and apo conditions. The only effect seen is again in the
glutamate-alone bound state, which shows a slight opening of the glutamatebound cleft relative to the glutamate-glycine bound state. The slightly more
closed cleft state at the glycine agonist-binding domain and a slightly more open
cleft at the glutamate agonist-binding domain in the presence of glutamate alone
observed in the MD simulations of interface II could contribute to these states in
the smFRET histograms (Figure 8 Ic 0.88 state and Figure 8 IIb 0.78 state,
respectively). However, the lack of no other changes suggests that the more open
cleft states relating to the cooperativity observed in the smFRET data are most
likely mediated by interface I.
Role of interface I in negative cooperativity. To test the results of the MD
simulations that show larger changes in the minimal construct for interface I with
similar trends as the smFRET data in the full length receptor in the different
liganded states, we performed smFRET measurements on the glycine-binding
domain of the receptor with GluN1 in complex with GluN2A E427G. This mutation
in GluN2A is present at interface I (Figure 10a inset) and has been previously
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shown to not exhibit cooperativity between glycine and glutamate (32); the glycine
off rates were similar in the absence and presence of glutamate and in fact slower
in both cases than that observed for wild type receptor. The smFRET histograms
(Figure 10) show a loss of the more open cleft states of the second agonist binding
site when agonist is bound to the first site than is seen in wild type background
(compare Figure 10c to Figure 8 Ic) confirming the role of those states in mediating
negative cooperativity. Additionally, there is also a decrease in the transition
probability for the single agonist glutamate bound receptor with the apo receptor
showing the highest transition probabilities. This is in contrast to what was
observed in the “wild-type” protein where the second agonist binding site showed
frequent transitions when agonist was bound to the first site. This indicates that
dynamics, the increase in probability of the transitions, in the second agonist site
when agonist is bound to the first site can also contribute towards the negative
cooperativity. Finally, a higher proportion of the more closed cleft conformations
is seen in the histograms under all liganded conditions relative to wild type
background. The higher fraction of the more closed cleft conformations could be
related to the slower off rates seen in this mutant protein relative to wild type (32).
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Figure 10: Measurements of the Glycine-Binding Domain in a Mutant Receptor
smFRET histograms (A–D) and state transition probability maps (E–H) for
the glycine-binding domain in the context of a GluN2A E427G mutant receptor.
smFRET data of the GluN1*-ABD/GluN2A*-E427G receptor was used to generate
smFRET efficiency histograms. The observed histograms are shown in gray and the
denoised histograms are shown in color. Individual states identified by STaSI
analysis are labeled according to their efficiencies. The observed histograms were
fit to Gaussian curves, and the cumulative Gaussian fit is shown as a gray curve.
Additionally, the state transition probability maps for each condition are shown. A
total of 1 mM glutamate and/or glycine was used as needed for the various
conditions studied. Conditions shown are apo (A and E), glycine-bound (B and F),
glutamate-bound (C and G), and glutamate-glycine-bound (D and H).
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We also functionally tested the role of interface I in mediating negative
cooperativity by introducing a cross-link across interface I between the GluN1 and
GluN2A subunits. A photoactivatable unnatural amino acid, p-benzoyl-Lphenylalanine (BZP), was introduced at site 700 on GluN1 (Figure 11a), and cells
expressing the modified receptors were exposed to UV light in the presence of
glutamate and glycine. The cross-linking across subunits was confirmed by
western blotting. The glycine off rates for the crosslinked receptor in the presence
and absence of glutamate show a significant decrease in cooperativity (Figure 11bd), with glutamate causing the glycine to dissociate from the receptor only 1.4
times faster compared to the greater than 3 fold increase seen in the wild type
receptor. Although there is a fraction of the receptors that are not crosslinked, the
trend of a reduction in negative cooperativity confirms the involvement of
interface I in mediating the negative cooperativity.
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Figure 11: Effect of Interface I Cross-linking on Negative Cooperativity
(A) The location of site 700 on GluN1 where the photoactivatable unnatural
amino acid BZP was incorporated is shown as a red sphere in the context of
interface I with GluN1 in tan and GluN2A in blue. (B and C) Measurements of the
rate of glycine deactivation or dissociation in the presence or absence of glutamate
using BZP cross-linked receptors. Experiments were performed using 100 μM
glycine, 1 mM glutamate, and 10 nM MeICA. (D) The ratio of the deactivation time
constants without glutamate to with glutamate for the noncross-linked receptors
(WT) and the BZP cross-linked receptors (700BZP). The negative cooperativity
effect of glutamate has been significantly reduced when compared to the
noncross-linked receptor.
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Conformational landscape at the transmembrane segments. In order to
measure the distance across the GluN1 transmembrane segments, the GluN1*TMD/GluN2A* receptor was used (Figure 12 I inset), and to measure the distance
across GluN2 the GluN1*-streptag/GluN2A*-TMD receptor was used (Figure 12 II
inset). The functionality of the GluN1*-streptag/GluN2A*-TMD receptor construct
was verified (Figure 18) and that for GluN1*-TMD/GluN2A* has been previously
reported (63). It has previously been shown that under resting apo conditions the
smFRET histogram for the GluN1 transmembrane region is shifted towards high
FRET states relative to what is observed for the glutamate-glycine bound form of
the receptor (63) (Figure 12 Ia and Figure 12 Id). Based on the structures of the
closely related Na+/K+ channels, for which the structures of the closed and open
channel states are known (159, 160), we could conclude that the lower FRET
efficiency states exhibited by the GluN1 transmembrane region could represent
open or pre-open channel states, which in turn is consistent with the occupancy of
these low FRET states occurring only in the presence of both agonists. Here we
show that addition of a single agonist glycine or glutamate (Figure 12 Ib and Figure
12 Ic) only populated the high FRET states showing that the lower FRET open/preopen states are not populated in the presence of a single agonist. A similar trend is
also observed for the smFRET measurements across the GluN2A transmembrane
segments when measured at a site equivalent to that of the GluN1 transmembrane
segments (Figure 12 II). The apo state of the GluN2A transmembrane segments
shows high FRET states (Figure 12 IIa), while the addition of glutamate with
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glycine caused the receptor to populate the 0.47 low FRET efficiency state that was
not observed in the apo state (Figure 12 IId). Binding of glutamate alone and
glycine alone does not populate states below FRET efficiency of 0.5, but instead
remains in states that are tightly packed (Figure 12 IIb and Figure 12 IIc). These
results show that both agonists are needed to populate the lowest efficiency state.
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Figure 12: Measurements of the Transmembrane Domain
smFRET histograms (A–D) and state transition probability maps (E–H) for
the transmembrane region of the (I) GluN1 and (II) GluN2A subunits. smFRET
data of the GluN1*-TMD/GluN2A* receptor or the GluN1*-streptag/GluN2A*-TMD
receptor was obtained and used to generate smFRET efficiency histograms. The
observed histograms are shown in gray and the denoised histograms are shown in
color. Individual states identified by STaSI analysis are labeled according to their
efficiencies. The observed histograms were fit to Gaussian curves, and the
cumulative Gaussian fit is shown as a gray curve. Additionally, the state transition
probability maps for each condition are shown. A total of 1 mM glutamate and/or
glycine was used as needed for the various conditions studied. GluN1 apo and
glu/gly data (A, E, D, and H in panel I) are from (63). Conditions shown in both
panels I and II are apo (A and E), glycine-bound (B and F), glutamate-bound (C
and G), and glutamate-glycine-bound (D and H).
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Conformational fluctuations at the transmembrane segments versus agonistbinding domain. The state transition probability maps for the GluN2A
transmembrane domain show that the apo receptor has the lowest number of
transitions, the glutamate alone and glycine alone bound receptors are
intermediate, and the glutamate-glycine-bound receptor has the highest number
of transitions (Figure 12 IIe-h). When these observations are contextualized to the
changes observed in the smFRET data at the agonist-binding domain, one can see
an inverse relationship between the transmembrane and agonist-binding domains
emerge. Under apo conditions the GluN1 and GluN2A agonist-binding domains
show large transitions (Figure 8 Ie and Figure 8 IIe) while the transmembrane
segments show very few transitons (Figure 12 Ie and Figure 12 IIe). Additionally,
the glutamate and glycine bound forms show fewer transitions at the agonistbinding domains (Figure 8 Ih and Figure 8 IIh) but show a large number of
transitions at the transmembrane domains (Figure 12 Ih and Figure 12 IIh).
Interestingly, the glutamate alone and glycine alone bound reeptors show that
when one agonist is bound the second agonist-binding domain has a large number
of transitions (Figure 8 If-g and Figure 8 IIf-g), however there are fewer transitions
in the transmembrane segments (Figure 12 If-g and Figure 12 IIf-g). Thus it appears
that in allowing the second agonist-binding domain to be more dynamic the
receptor ensures that the transmembrane segments are still tightly closed and do
not populate the open channel states seen when both agonists are bound.
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It should be noted that a direct comparison between the FRET based distances and
structures is not possible as the specific residue used for labeling is not resolved in
the current structures, expect in one glycine and glutamate bound structure
(PBD:6IRA) where the GluN1-GluN1 distance is 36 Å (17). This is similar to the
highest occupancy smFRET state, which has a distance of 40 Å.

Discussion:
Historically, allostery in structured proteins has been interpreted in terms
of the propagation of rigid body structural changes that are induced by agonist or
effector binding. The NMDA receptor is an example of such studies where the end
states have been well characterized (16, 29, 30, 158), and based on these structures
the allosteric mechanism of activation has been established to be a cleft closure at
the agonist-binding domains leading to motion at the transmembrane segments
which results in activation. While these simplistic models are able to provide a
framework for structure-function correlations, recent studies show conformational
landscape and transition dynamics play essential roles in mediating allosteric
communications across subunits (145, 146, 161). Here we show that negative
cooperativity between glutamate and glycine as well as activation of the NMDA
receptor is mediated through the intricate interplay of conformational landscape
and transitions within that landscape between the different domains in this
receptor. The smFRET and MD simulations presented show that the binding of an
agonist at one site increases the spread of states and transitions between the states
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in the second agonist-binding subunit. The ‘destabilization’ of the closed cleft state
at the second site can be tied back to the lower affinity of the second agonist when
the first agonist is present and thus underlies the negative cooperativity observed.
The NMDA receptors are unique among the ionotropic glutamate receptors
in having an extensive interface between the GluN1 agonist binding domain and
the GluN2 amino terminal domain (Figure 9 Ia), in addition to the back-to-back
interface of the agonist-binding domains (Figure 9 IIa). The role of interface II (the
interface within the dimer in the agonist binding domains of GluN1 and GluN2A)
has been studied extensively as this interface was first observed in the initial
crystal structures of the isolated agonist-binding domain (155). Interface II is
similar to what is observed in the AMPA and kainate receptors, and it is the site of
binding of allosteric modulators and ions (162, 163). In NMDA receptors, a
mutation at site Y535 in this interface has been shown to alter deactivation.
Interface II is also the site of positive and negative allosteric modulators (164, 165).
We hence performed MD simulations on this dimer construct to determine its
contributions towards negative cooperativity. Our data show that the binding of
glutamate alone causes the glycine cleft to adopt a more closed conformation
relative to no ligand being present at both domains which would suggest a slower
dissociation of glycine in the presence of glutamate and is more consistent with
positive cooperativity and not negative cooperativity, counter to observations
using electrophysiology and spectroscopy. MD simulations on interface I (the
inter-dimer interface between the agonist-binding domain of GluN1 and the amino
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terminal and agonist-binding domains of GluN2A), on the other hand show trends
similar to what is observed in the smFRET measurements.
Previous structural and functional studies have shown the importance of
interface I in mediating zinc allosteric inhibition, gating, and agonist efficacy (18,
32, 154). Specifically, Esmenjaud, et al. demonstrated that the introduction of
cysteine crosslinks across interface I, between the agonist-binding domains of
GluN1 and GluN2, can lock the receptor into an active, “rolled” conformation (154).
The receptor locked into the “rolled” conformation also demonstrated increased
EC50 values for both glycine and glutamate. Additionally, Regalado, et al. showed
that a mutation, E427G, at this interface eliminated the negative cooperativity (32).
Here we performed smFRET measurements on this mutation and show a loss in
the more open cleft state and a reduction in the higher state transitions dynamics
at the glycine site in the presence of glutamate. These data further confirm the role
of these states and dynamics in mediating negative cooperativity. The selective loss
of the more open cleft state in the E427G mutant also suggests that the more open
cleft states observed at the second agonist binding domain are not likely due to an
unstable fragile state of the receptor due to sample preparation in the smFRET
measurements.
The smFRET measurements at the transmembrane domain were performed
to determine the changes at the functional segment of the protein due to single
agonist binding. These data show tightly packed states at the pre-M1 helices of
both subunits of the NMDA receptor in the presence of single agonist. It is
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interesting to note that the binding of glycine alone shows a higher fraction of the
lower FRET efficiency state for measurements across both GluN1 and GluN2,
relative to the glutamate-alone bound state. Additionally, the dynamics of the
changes at the GluN1 transmembrane domain are larger in the glutamate-glycine
bound state relative to what is observed across the GluN2 subunits. Prior
functional measurements have shown differences in the extent of agonistactivation coupling for glutamate and glycine and these differences seen in the
smFRET measurements here may be reflective of these differences (166). Further,
the absence of more loosely packed transmembrane states in the single agonist
bound state suggests that the negative cooperativity may be a mechanism to
ensure that the conformational entropy loss associated with binding of a single
agonist at its binding site is transmitted to the adjacent agonist-binding domain
and not the transmembrane segments. Thus ensuring that the receptor only opens
in the presence of both agonists and emphasizing the role of allostery in fine
tuning regulation.
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Chapter 4: Measurements of the NMDA Receptor Conformational
Landscape in the Presence of a Partial Agonist
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Introduction:
Glutamate Receptor Significance and Partial Agonism
Glutamatergic signaling, which accounts for the majority of excitatory
neurotransmission in the human central nervous system, is mediated in large part
by ligand-gated ion channels known as ionotropic glutamate receptors (iGluRs)
(3). These receptors bind to glutamate in the extracellular space and open a cationpermeable channel in the plasma membrane. The family of iGluRs is divided into
subtypes based on agonist selectivity profiles. One such subtype of iGluR is the Nmethyl-D-aspartate (NMDA) receptor, which is involved in the physiological
processes of learning and memory formation (8, 9). Furthermore, the NMDA
receptor has been implicated in various neurological diseases and conditions
including ischemic stroke, epilepsy, and schizophrenia (10-14). Understanding the
structure-function relationship within NMDA receptors therefore has important
physiological and therapeutic implications.
Under typical conditions, the NMDA receptor binds its agonist glutamate
and also binds an obligate co-agonist glycine or D-serine which then leads to
receptor activation and ion channel formation (3-5). Importantly, there are also a
number of known partial agonists of the NMDA receptor that activate the receptor
to a lesser degree than the typical agonists even under saturating conditions (3).
The mechanism by which partial agonists activate the NMDA receptor to a
submaximal degree is not fully understood, and understanding of that mechanism
could yield insight into how to modulate the degree to which NMDA receptors are
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activated as a therapeutic approach to the above-mentioned neurological
problems.
Prior studies have explored the mechanism of partial agonism in the NMDA
receptor. Structural studies have examined the conformational changes induced by
full and partial agonists in the agonist-binding domain of NMDA receptors and
found no difference between the two (15, 40), thereby indicating that static
structural studies will need to be supplemented with studies of the receptor’s
dynamic behavior in order to fully understand the mechanism of partial agonism.
Single-molecule FRET measurements of the NMDA receptor agonist-binding
domain have also been performed in an attempt to understand the mechanism of
partial agonism and showed that the ability of an agonist to shift the agonistbinding domain into a closed conformation correlated well with the extent of
activation by that agonist (41). One limitation of this approach, however, is that
the measurements were made on the isolated glycine-binding domain of the
NMDA receptor. It is known that the glycine- and glutamate-binding domains of
the NMDA receptor engage in allosteric communication, with the binding of
agonist at one site affecting the other site (148, 149, 167). It becomes necessary,
therefore, to examine the mechanism of partial agonism in the NMDA receptor
using methods that can address the dynamic motions of the receptor in its fulllength form. Herein, we present single-molecule FRET data, electrophysiological
measurements, and molecular dynamics simulations that address the mechanism
underlying partial agonism in the NMDA receptor.
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NMDA Receptor Structure
The NMDA receptor is an obligate hetero-tetramer. Two subunits of the
receptor are of the GluN1 subtype, which contains the glycine binding site. In the
most abundant form of the NMDA receptor, the other two subunits are of the
GluN2A subtype, which contains the glutamate binding site (16, 29-31). These
subunits are arranged in an alternating pattern, such that each GluN1 is bordered
by two GluN2A subunits and vice-versa. Because the four subunits are arranged as
two dimers, this leads to each subunit having one intra-dimer and one inter-dimer
interface with the adjacent subunits. The subunits are structured in a modular
fashion, containing several domains. The amino-terminal domains and agonistbinding domains constitute the extracellular portion of the receptor. The agonistbinding domains are of particular interest in this study as they are the sites of
glycine and glutamate binding. The agonist-binding domains of the NMDA
receptor are clamshell-shaped, possessing two lobes each that are connected by a
hinge. The upper (N-terminal) lobe is known as D1, while the lower (C-terminal)
lobe is known as D2. For our fluorescent measurements of the GluN1 and GluN2A
agonist-binding domains, we have selected fluorophore attachment sites on
opposite lobes of each domain such that we can measure the degree to which a
given domain is in an open or closed clamshell conformation (Figure 13a inset and
Figure 13d inset). In addition to the extracellular domains, the NMDA receptor
also possesses a transmembrane domain, which is responsible for forming the ion
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channel. Finally, each subunit contains an intracellular C-terminal domain which
can vary greatly between different subunit subtypes and the structure of which has
not yet been determined. Herein, we have investigated the structural landscape of
the NMDA receptor in an attempt to understand the mechanism of partial
agonism in the receptor.

Results
Partial Agonist Effects on the GluN1 Agonist-Binding Domains
In order to begin our investigation into the mechanism of partial agonism
in the NMDA receptor, we selected an NMDA receptor partial agonist called 1Aminocyclobutanecarboxylic acid (ACBC). ACBC is a glycine-site partial agonist
that binds to the agonist-binding domain of the GluN1 subunit and activates the
GluN1/GluN2A NMDA receptor to 13% of the maximal response (38). This partial
agonist was selected as it will allow for a study of the receptor at an intermediate
level of activation, enabling the investigation of intermediate states that are
involved in controlling efficacy of agonists. Additionally, prior studies of the
isolated GluN1 domain have been conducted using ACBC (41, 89), so using this
partial agonist allows for a comparison of the differences between the isolated
domain and the full-length receptor.
Because the partial agonist ACBC binds to the agonist-binding domain of
the GluN1 subunit, we began our studies by conducting single-molecule FRET
(smFRET) measurements of the agonist-binding domains of the NMDA receptor in
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order to determine the effects of partial agonist binding on the conformation of
those domains. In order to perform these smFRET experiments, we began by
transfecting HEK293 cells with GluN1 and GluN2A DNA constructs that are
designed to provide fluorophore labeling sites that report on the conformation of
the agonist-binding domains of the receptor. After allowing for expression of the
NMDA receptor molecules, the cells were exposed to donor (Alexa 555) and
acceptor (Alexa 647) fluorophores to label the NMDA receptor molecules.
Following preparation of membrane fractions from the labeled HEK293 cells and
subsequent pull-down of NMDA receptors onto the smFRET slides, we performed
smFRET measurements of the agonist-binding domains of the receptor.
The GluN1 agonist-binding domain in the presence of ACBC alone (with no
agonist at the GluN2 site) exhibits three states (0.77, .87, and .95) with the overall
distribution of FRET efficiencies favoring the highest FRET state (0.95) (Figure
13a). The two high FRET states 0.87 and 0.95 in the presence of ACBC alone are
similar to the 0.83 and 0.93 FRET efficiencies that were observed previously when
only glycine (a GluN1 full agonist) is bound to the receptor (53). The similar high
FRET states for ACBC- and glycine-bound conditions are consistent with the prior
structural studies that show the GluN1 agonist-binding domain to be primarily in a
closed cleft confirmation in both full- and partial-agonist-bound states (15, 40).
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Figure 13: Single-molecule FRET Measurements of the NMDA Receptor AgonistBinding Domains in the Presence of a Partial Agonist
Single-molecule FRET histograms showing the conformational landscape of
the GluN1 agonist-binding domain in the presence of A) GluN1 partial agonist
ACBC and B) ACBC with GluN2A full agonist glutamate (colored lines).
Histograms are fit with multiple Gaussian curves (black) to show the underlying
conformational states. Individual states are labeled by their FRET efficiency. Panel
A inset shows the location of the fluorophore attachment sites (red spheres, S507
and T701) within the context of the NDMA receptor structure (PDB: 7EOS (24)). C)
Overlay of smFRET histograms in the presence of ACBC with and without
glutamate compared to that in the presence of GluN1 full agonist glycine with
glutamate (glycine with glutamate data previously published in (53)). D-F) The
same as A-C, but for the GluN2A agonist-binding domain. Panel D inset shows
fluorophore attachment sites Q503 and M702.
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Upon addition of both GluN1 partial agonist ACBC and GluN2A full agonist
glutamate, the GluN1 agonist-binding domain still exhibits the same three
conformational states as were observed in the presence of ACBC alone (Figure 13ab). However, the overall distribution of FRET efficiencies is left-shifted towards
low FRET. This low FRET state corresponds to a longer distance across the cleft
and hence a more open cleft conformation of the domain (Figure 13b). This
indicates that the binding of glutamate to the GluN2A subunit allosterically causes
a shift towards open-cleft conformations in the GluN1 agonist-binding domain. A
similar shift to lower FRET was observed in the GluN1 agonist-binding domain
when bound to full agonist glycine in the presence of glutamate at GluN2A relative
to in the absence of glutamate (53). Importantly, the left-shift induced by
glutamate binding is greater when partial agonist ACBC is bound to the receptor
compared to when full agonist glycine is bound (Figure 13c). As cleft closure at the
agonist-binding domains is associated with receptor activation, this shift in
conformational landscape at the GluN1 agonist-binding domain to more open cleft
conformations could underlie the difference in efficacy exhibited by the partial
agonist ACBC versus full agonist glycine.

Partial Agonist Effects on the GluN2A Agonist-Binding Domains
In addition to the measurements at the GluN1 agonist-binding domain, we
performed measurements of the GluN2A agonist-binding domain. When the
domain was measured in the presence of ACBC, we saw four states (0.46, 0.66,
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0.79, and 0.91) (Figure 13d). These four states in the presence of GluN1 partial
agonist ACBC alone align well with the four states that were observed previously at
the GluN2A agonist-binding domain in the presence of only GluN1 full agonist
glycine (53). The similar spread of states in the ACBC alone and glycine alone
conditions indicates that the efficacy of the agonist at the GluN1 agonist-binding
domain does not exhibit a strong effect on the GluN2A agonist-binding domain
when glutamate is not present.
When measured in the presence of GluN1 partial agonist ACBC with
GluN2A full agonist glutamate, the GluN2A agonist-binding domain shows four
states (0.59, 0.75, 0.85, and 0.96) that exhibit a right-shift towards high FRET as
compared to in the presence of ACBC alone (Figure 13d-e). This shift towards high
FRET is consistent with previous studies that show that glutamate binding to the
GluN2A agonist-binding domain induces a shift towards high FRET states (53).
As we did for the GluN1 agonist-binding domain, we compared the FRET
efficiency distributions in the presence of ACBC alone and ACBC with glutamate
to what was previously reported in the presence of glycine with glutamate (53). It
is clear from this comparison (Figure 13f) that glutamate induces a right-shift in
the FRET efficiency distribution of the GluN2A agonist-binding domain regardless
of whether partial agonist or full agonist is bound to the GluN1 agonist-binding
domain. We have also observed, however, that the full agonist glycine-bound
distribution is significantly more right-shifted than the partial agonist ACBCbound form. This result indicates that the partial agonist ACBC causes the GluN2A
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agonist-binding domain to favor relatively open conformations compared to the
full agonist glycine. This increase in open-cleft conformations in the presence of
partial agonist relative to full agonist could underlie the reduced efficacy of the
partial agonist relative to the full agonist.

Electrophysiological Measurements of Partial Agonist Effect on Glutamate
Because we observed with the smFRET measurements of the agonistbinding domains that the glutamate-binding domain is more open in the presence
of ACBC versus glycine, we investigated whether this phenomenon could have an
effect on the dissociation rate of glutamate from the glutamate-binding site of the
receptor. To answer this question, we made electrophysiological measurements of
the dissociation of glutamate from the NMDA receptor in the presence of the full
and partial agonist. In order to do this, we first took membrane patches from
NMDA receptor-expressing HEK293 cells and equilibrated those patches in a
solution of glutamate to ensure that the glutamate-binding sites were saturated.
We then rapidly switched the membrane patches into a solution containing either
full agonist glycine or partial agonist ACBC and observed the resulting current
decay. The rate of decay of the NMDA receptor-mediated current reflects the rate
of dissociation of glutamate from the receptor. Upon completing these
electrophysiological measurements, we found that glutamate dissociates from the
receptor more quickly in the presence of ACBC than it does in the presence of
glycine (Figure 14a), with glutamate exhibiting a time constant of dissociation of 11
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± 1 ms in the presence of ACBC and a time constant of dissociation of 51 ± 7 ms in
the presence of glycine (Figure 14b). This result might indicate why the ACBC
activates the receptor to a lesser degree than glycine if it causes the glutamatebinding domain to favor an open-cleft conformation that facilitates glutamate
unbinding.
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Figure 14: Electrophysiological Measurements of Glutamate Dissociation from the
NMDA Receptor
A) Electrophysiological traces obtained from NMDA-receptor-containing
membrane patches. Patches were equilibrated with GluN2A full agonist glutamate,
switched into solution containing glutamate and either GluN1 full agonist glycine
or GluN1 partial agonist ACBC, and then switched into solution containing only
glycine (black) or ACBC (blue). The resulting current decay was recorded and
indicates the rate of glutamate dissociation. B) Quantification of the time
constants of the current decay in the presence of glycine alone and ACBC alone.
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Molecular Dynamics Simulations of the Inter-subunit Interface
In order to understand the structural mechanism at play behind the effect
of the partial agonist on the glutamate-binding domain, we conducted Molecular
Dynamics simulations to observe the structural changes that could be controlling
this allosteric communication between subunits. For this study, we set up
simulations of both the intra-dimer and inter-dimer agonist-binding domain
interfaces. We simulated the interfaces in the presence of ACBC with glutamate
and then compared the results with previously published simulations in the
presence of glycine with glutamate (53). In order to compare the simulation results
with the results of our smFRET measurements of the receptor, we measured the
distance throughout the simulations between the points on the receptor where we
attached our fluorophores in the smFRET measurements to create histograms of
the distance distribution over the course of the simulation. For the intra-dimer
interface, the results show that the GluN1 agonist-binding domain undergoes a
shift towards more open conformations in the presence of ACBC with glutamate
compared to in the presence of glycine with glutamate (Figure 15a). This result is
consistent in trends with what was observed in the smFRET experiments (Figure
13c). We also examined the distance between fluorophore attachment sites for the
glutamate-binding domain in the intra-dimer simulations. Here, we see that the
domain is more open in the presence of ACBC with glutamate as compared to in
the presence of glycine with glutamate (Figure 15b). This result is again consistent
with what was observed in the smFRET measurements of the receptor (Figure 13f).
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Figure 15: MD Simulations of Agonist-Binding Domain Intra-dimer Interface
Histograms showing the distribution of distances between fluorophore
labeling sites in the simulations of the intra-dimer interface of the agonist-binding
domains for the A) GluN1 agonist-binding domain and B) GluN2A agonist-binding
domain. Data shown are in the presence of GluN1 partial agonist ACBC with
GluN2A full agonist glutamate (blue) or in the presence of GluN1 full agonist
glycine with glutamate (red). Glycine with glutamate data was previously
published in (53). Insets in A and B show the simulated domains in color in the
context of the overall receptor (gray) and sites between which measurements were
made (S507 and T701 for GluN1, Q503 and M702 for GluN2A) as red spheres. C)
Comparison of the structure of the GluN1 agonist-binding domain (the site of
glycine and ACBC binding) when simulated bound to glycine (orange) or ACBC
(blue). A coordinated shift in the D2 lobe towards the intra-dimer interface with
the GluN2A domain can be observed in the ACBC-bound simulation.
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When we performed simulations of the agonist-binding domain interdomain dimer, we saw the same trends as what was observed for the intra-domain
dimer, thus indicating that the simulations recapitulate the biological smFRET
measurements at both the intra- and inter-dimer agonist-binding domain
interfaces. This result was at odds with previous simulations of these interfaces
that we had performed (53) where we saw that the two interfaces mediated
opposite allosteric effects. Because the intra-dimer interface is exhibiting different
behavior in the partial agonist simulations from what it was showing in the full
agonist simulations, we decided to examine this interface in our current
simulations to determine what region of this interface could be mediating this
difference in behavior, as that difference could underlie the difference in agonist
efficacy.
Because we had observed large differences between the partial and full
agonist-bound forms of the receptor in the presence of glutamate, we compared
the simulation structure from the ACBC with glutamate simulation to that from
the glycine with glutamate simulation. This allowed us to observe differences in
structure at the intra-dimer agonist-binding domain interface between partial and
full-agonist bound forms of the receptor in the presence of glutamate. To perform
this comparison, we aligned the structures of the GluN1 D1 lobes from the ACBC
with glutamate simulation and the glycine with glutamate simulation to each
other. After performing this alignment, we observed that the D2 lobe of the ACBC
with glutamate simulation is shifted towards the inter-subunit interface with the
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adjacent GluN2A agonist-binding domain compared to that from the glycine with
glutamate simulation (Figure 15c). In particular, helices 1, 2, and 3 (Figure 15c) are
shifted towards the intra-dimer interface, with helix 1 in particular interacting
directly with the glycine/ACBC ligand. This shift in helix 1 and 2 could lead to
potential steric clashes with the GluN2A agonist-binding domain D1 lobe. This
interaction between the two subunits could be the reason for the GluN2A agonistbinding domain adopting a more open conformation in the presence of ACBC
versus glycine and could also be the reason for the increased dissociation rate of
glutamate from the GluN2A agonist-binding domain that we measured in Figure
14. This structural interaction may be responsible for allosterically transducing the
binding of ACBC from the GluN1 to the GluN2A subunit and leading to the
reduced efficacy of partial agonist ACBC compared to full agonist glycine.

Transmembrane Domain Measurements
The ultimate function of the NMDA receptor is to open an ion channel in
the plasma membrane of a neuron. The transmembrane domain (TMD) is the
section of the receptor responsible for forming the ion channel, so we have made
smFRET measurements of the TMD to determine the effects of the partial agonist
ACBC on the conformation of the ion channel. To make these measurements, we
selected fluorophore labeling sites at the pre-M1 helix of GluN1 and GluN2A
(Figure 16a inset and Figure 16d inset). Each pair will enable measurements across
the central ion channel pore. Furthermore, the two pairs of measurements are
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roughly perpendicular to each other, which will provide for a more complete
understanding of the motions of the entire TMD.
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Figure 16: Single-molecule FRET Measurements of the NMDA Receptor
Transmembrane Domains in the Presence of a Partial Agonist
Single-molecule FRET histograms showing the conformational landscape of
the GluN1 transmembrane domains in the presence of A) GluN1 partial agonist
ACBC and B) ACBC with GluN2A full agonist glutamate (colored lines).
Histograms are fit with multiple Gaussian curves (black) to show the underlying
conformational states. Individual states are labeled by their FRET efficiency. Panel
A inset shows the location of the fluorophore attachment sites (red spheres, F554)
within the context of the NDMA receptor structure (PDB: 7EOS (24)). C) Overlay
of smFRET histograms in the presence of ACBC with and without glutamate
compared to that in the presence of GluN1 full agonist glycine with glutamate
(glycine with glutamate data previously published in (53)). D-F) The same as A-C,
but for the GluN2A transmembrane domains. Panel D inset shows fluorophore
attachment sites F553.
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When we observe the GluN1 TMDs in the presence of ACBC, we can see a
distribution of three FRET states that favor high-FRET conformations of the ion
channel (Figure 16a). If we compare these smFRET measurements of the TMD of
the NMDA receptor to published structures of the structurally-similar Na/K
channels, we see that the high-FRET states match with a closed conformation of
the TMD (160). This result indicates that, as expected, the ion channel does not
probe open conformations when glutamate is not present. When we observe the
receptor in the presence of ACBC with glutamate, we see a fourth, low-FRET state
(0.63) appear (Figure 16b). This state corresponds well with the structure of the
open conformation of the Na/K channel (159), indicating that the TMD does probe
open channel conformations in the presence of partial agonist ACBC with
glutamate. As expected, the partial agonist does not shift the TMD to open states
to as great a degree as the full agonist glycine with glutamate, as shown by
comparing the FRET distribution to that which was previously determined in the
presence of the full agonists (53) (Figure 16c).
In addition, observations at the corresponding GluN2A TMD showed that,
like at the GluN1 TMD, the receptor in the presence of ACBC shows a distribution
of three high-FRET states (Figure 16d). This again indicates that the TMD stays in a
closed conformation in the absence of glutamate. Similar to the GluN1 TMD, we
see that, in the presence of both partial agonist ACBC and full agonist glutamate,
the GluN2A TMD exhibits a low-FRET state (0.61) that was not observed in the
presence of ACBC alone (Figure 16e). This low-FRET state probably corresponds to
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an open-channel conformation of the receptor. When we compared these results
to those seen in the presence of glycine and glutamate (53), it is clear that the
occupancy of the low-FRET states is lower with ACBC and glutamate than it is
with glycine and glutamate (Figure 16f). This result was expected as the partial
agonist activates the receptor to a lesser degree and therefore should not shift the
receptor into an active conformation as often as the full agonist should. These
results indicate the mechanism by which the receptor is less activated by the
partial agonist than by the full agonist; the partial agonist does not induce ion
channel opening nearly as much as the full agonist does.

Amino-Terminal Domain Measurements
In addition to the agonist-binding and transmembrane domains, the
NMDA receptor also possesses amino-terminal domains (ATDs) that lie adjacent
to the agonist-binding domains and are known to engage in allosteric modulation
of NMDA receptor activity. In an attempt to gain a complete understanding of the
conformational rearrangements of the NMDA receptor in response to agonists, we
conducted smFRET measurements between the GluN2A ATDs in the presence of
partial agonist ACBC, ACBC with full agonist glutamate, and full agonist glycine
with glutamate. In the presence of ACBC, we observe three FRET states, with the
lowest FRET state (0.59) exhibiting only a very small fraction of the overall FRET
distribution (<5%) (Figure 17a). In the presence of ACBC with glutamate, the
overall distribution of FRET states does not change significantly from the
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distribution as seen in the presence of ACBC alone (Figure 17b). Notably, the
lowest FRET state (0.58) still exhibits a very small fraction of the overall FRET
distribution. Interestingly, when the ATDs are measured in the presence of full
agonists glycine with glutamate, the occupancy of the lowest FRET state (0.62)
increases by over three fold (Figure 17c). This shift in occupancy towards the
lowest FRET state leads to an overall left shift in the FRET efficiency distribution
that indicates that the ATDs tend to be farther apart from each other in the
presence of the two full agonists as opposed to in the presence of partial agonist
ACBC (Figure 17d).
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Figure 17: Single-molecule FRET Measurements of the NMDA Receptor AminoTerminal Domains
Single-molecule FRET histograms showing the conformational landscape of
the GluN2A amino-terminal domains in the presence of A) GluN1 partial agonist
ACBC, B) ACBC with GluN2A full agonist glutamate, and C) GluN1 full agonist
glycine with glutamate (colored lines). Histograms are fit with multiple Gaussian
curves (black) to show the underlying conformational states. Individual states are
labeled by their FRET efficiency. Panel A inset shows the location of the
fluorophore attachment sites (red spheres, T174) within the context of the NDMA
receptor structure (PDB: 7EOS (24)). D) Overlay of smFRET histograms in the
presence of ACBC with and without glutamate compared to that in the presence of
glycine with glutamate.
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It has been shown previously that the NMDA receptor ATDs tend to adopt
splayed apart conformations under conditions in which they are inhibited in
function (18). In line with these results, we are proposing that the low-FRET state
that we have observed at the GluN2A ATDs corresponds with a desensitized
conformation of the NMDA receptor. According to our smFRET results, the ATDs
do not shift into the low-FRET conformation when in the presence of ACBC or
ACBC with glutamate and only shift into the low-FRET state at high levels when in
the presence of full agonists glycine and glutamate. We see, therefore, that the
ATDs do not rearrange during activation of the receptor but rather only when the
receptor shifts into a desensitized state.

Discussion
Prior studies of the NMDA receptor using static structural methods have
shown no difference between the conformational arrangement of the GluN1 ABD
in the presence of full agonist versus that in the presence of partial agonist (15, 40).
The smFRET studies presented herein, however, have been able to identify
changes in the structural landscape of the agonist-binding domains when bound
to agonists of varying efficacy. The underlying conformational states that we have
identified for each domain do not change significantly when the receptor is shifted
to be in the presence of a different combination of agonists (see this work and
(53)); what does change significantly is the relative population of the different
states. One limitation of static structural measurements is that they may only
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capture the state or states that are most amenable to static structural analysis.
Static structural studies remain an extremely insightful and powerful method for
understanding protein structure, but dynamic studies of protein structure can
serve as a critical tool for understanding the conformational changes that control
protein function.
In light of the importance of dynamic studies of protein structure, prior
dynamic studies of the NMDA receptor have been performed to understand the
effect of dynamic motions on the function of the NMDA receptor (41, 89). These
studies provided important insight into the behavior of the GluN1 agonist-binding
domain in the presence of agonists of varying efficacy, but one limitation of these
studies was their inability to understand the effects of inter-subunit interactions
within the NMDA receptor due to their being carried out on the isolated GluN1
agonist-binding domain. Because the GluN1 and GluN2A agonist-binding sites of
the receptor have been previously shown to engage in allosteric communication
with each other (148, 149, 167), it is important to study the effect of agonists of
varying efficacy in the context of the full length receptor. The studies presented
herein have served as a next step to the studies that were performed on the
isolated domain by elucidating the inter-subunit conformational effects of partial
agonist binding in the NMDA receptor.
Taken together, the results presented herein provide insight into the
structural mechanism of partial agonism within the NMDA receptor. Through our
observations of the GluN1 agonist-binding domain, we have seen that the GluN1
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partial agonist ACBC enhances the ability of the GluN2A full agonist glutamate to
allosterically cause the GluN1 agonist-binding domain to adopt a more open
conformation. Additionally, through our observations of the GluN2A agonistbinding domain, we have seen that ACBC allosterically causes the GluN2A agonistbinding domain to adopt an even more open conformation than the GluN1 full
agonist glycine does. Therefore, we have observed that ACBC enhances the ability
of the agonist-binding domains of the NMDA receptor to allosterically affect each
other both in a GluN1 to GluN2A direction and vice-versa. These results were
unexpected; our prior studies of the agonist-binding domains had shown that full
agonist binding at one of the agonist-binding domain causes the other agonistbinding domain to adopt a more open conformation (53), but we originally
expected a partial agonist to have an effect that was less than that of the full
agonist, not greater. We, therefore, are proposing that the increased degree of
allosteric communication between the two agonist-binding domains of the NMDA
receptor that we have observed herein with the partial agonist ACBC is responsible
for the decreased efficacy of the partial agonist. In support of this idea, the
increased degree of openness that we observed at the GluN2A agonist-binding
domain in the presence of ACBC correlates with an increased rate of glutamate
dissociation from the NMDA receptor as observed by electrophysiology. These
results indicate in both a structural and functional capacity that ACBC alters the
degree of openness at the agonist-binding domains of the NMDA receptor.
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To elucidate the mechanism by which ACBC is causing a stronger allosteric
effect than that caused by the full agonist glycine, we turned to molecular
dynamics (MD) simulations and observed a structural shift in the D2 lobe of the
GluN1 agonist-binding domain in the presence of ACBC with glutamate versus in
the presence of glycine with glutamate. This structural shift would lead certain
alpha helices of the GluN1 agonist-binding domain to interact with the GluN2A
agonist-binding domain across the intra-dimer interface, thereby creating a
structural pathway through which allosteric effects could be transmitted from one
agonist-binding domain to the other. We propose that this interaction could
explain the structural mechanism by which the agonists at the agonist-binding
domains of the NMDA receptor are allosterically affecting each other.
In addition to our measurements at the agonist-binding domains of the
receptor, we also conducted observations of the transmembrane domains of the
NMDA receptor that yielded the expected results that the partial agonist does not
cause the ion channel pore to adopt an open conformation as much as the full
agonist. This result is important, as it confirms that our smFRET structural
measurements accurately recapitulate the functional effects of partial agonist vs
full agonist binding in the NMDA receptor. Finally, we also see through our
amino-terminal domain measurements that that domain shifts conformation only
in the extreme state of having both full agonists bound to the receptor. We
interpret this to indicate that the GluN2A ATDs do not shift significantly in
conformation relative to each other except during receptor
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activation/desensitization. All of the above structural measurements serve to
illustrate the conformational rearrangements that control receptor activation. By
comparing the conformational landscape of the receptor bound to a partial agonist
to that of the receptor when bound to a full agonist, we have gained insight into
the conformational motions that control agonist efficacy in the NMDA receptor.
In order to gain an even more detailed understanding of NMDA receptor agonist
efficacy, several future directions need to be explored. Firstly, additional studies of
the NMDA receptor conformational landscape need to be performed using other
GluN1 site partial agonists of the NMDA receptor. Herein, we have compared the
effect of glycine, which produces a 100% activation of the receptor, to ACBC, which
produces a 13% activation of the receptor. It is easy to see how additional studies of
partial agonists that activate the receptor between 100% and 13% would shed light
on how these conformational changes are altered as the agonist efficacy
approaches that of the full agonist. Sampling several agonists of varying efficacy
could provide additional data points for comparing the effect of raising the agonist
efficacy on the overall conformational landscape of the agonist-binding domains of
the receptor, thereby providing a strong understanding of which conformational
changes control agonist efficacy. Additionally, it is critical to study GluN2A site
partial agonists to determine what the conformational changes are that control
partial agonism at that site. Performing the same sort of study with a variety of
partial agonists of varying efficacies at the GluN2A site would provide a similarly
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detailed picture of the conformational mechanisms controlling GluN2A agonist
efficacy.
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Chapter 5: Materials and Methods

This chapter is based upon a prior publication: Durham, R.J., Paudyal, N.,
Carrillo, E., Bhatia, N. K., Maclean, D. M., Berka, V., Dolino, D. M., Gorfe, A. A.,
and Jayaraman, V. 2020. Conformational spread and dynamics in allostery of
NMDA receptors. PNAS 117(7) 3839-47 (53). This work has been reproduced here
with permission from PNAS.

Individual contributions to the methods described below are as follows:
Elisa Carrillo preformed the electrophysiology and composed the section on
electrophysiology methods, Nabina Paudyal composed the section on Molecular
Dynamics simulations methods, and Ryan J. Durham composed all other sections
of the methods. Express written permission to use this work in this thesis has been
obtained from all co-authors.
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The materials and methods employed in the various studies presented
above are as follows:

DNA Construct Design
Wild type Rattus norvegicus GluN1 and GluN2A (provided by S. Nakanishi
(Osaka Bioscience Institute, Osaka, Japan)) were mutated such that all
extracellular non-disulfide-bonded cysteines were changed to serines (C459 in
GluN1) (C231, C399, and C460 in GluN2A). These “cys-light” constructs (GluN1*
and GluN2A*) were further modified using site-directed mutagenesis to create the
constructs used in the smFRET experiments. For the first construct, a C-terminal
Twin-Strep tag was added to the GluN1* (GluN1*-streptag). For the second
construct, T701 and S507 of the GluN1* were changed to cysteines (GluN1*-ABD).
For the third construct, F553 of the GluN2A* was changed to a cysteine (GluN2A*TMD). For the fourth construct, Q503 and M701 of the GluN2A* construct were
changed to cysteines (GluN2A*-ABD). All constructs are contained in the pcDNA
3.1 vector and have been shown via electrophysiology to form functional receptors
(Figure 18 and Figure 19). The GluN1*-TMD construct consists of the GluN1* with
F554 changed to a cysteine. This construct has been previously used and shown to
be functional by electrophysiology (63). For the smFRET on the mutant GluN2A
receptor, E427 of GluN2A* was changed to a glycine (GluN2A*-E427G). For the
amino-terminal domain measurements, we introduced a cysteine at site T174 in
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GluN2A (GluN2A-ATD). All mutations were verified with Sanger sequencing
(Genewiz, NJ).
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Figure 18: Characterization of smFRET Constructs for Negative Cooperativity
Studies
Representative whole cell electrophysiological responses from modified
NMDA receptors used in the studies presented in Chapter 3. Traces were obtained
via application of 1mM glutamate and 1mM glycine and recorded at -60mV with
appropriate fluorophores already attached at the smFRET labeling sites.
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Figure 19: Characterization of smFRET Constructs for Partial Agonist Studies
Representative whole cell electrophysiological responses from modified
NMDA receptors used in the studies presented in Chapter 4. Traces were obtained
via application of glutamate with glycine (black) or glutamate with ACBC (blue).
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smFRET Sample Preparation
HEK293T cells (ATCC, Manassas, VA) were cultured at 37°C and 5% CO2 in
Dulbecco’s

Modified

Eagle’s

Medium

(DMEM)

(GenDepot,

Barker,

TX)

supplemented with 10% Fetal Bovine Serum (FBS) (GenDepot) and 1 unit/mL
Penicillin/ 1 ng/mL Streptomycin (P/S) (Sigma-Aldrich, St. Louis, MO). The cells
were transiently transfected using jetPRIME reagent (Polyplus, Berkeley, CA)
according to the manufacturer’s protocol using 10µg of DNA per 10cm dish in a
1µg:3µg ratio of GluN1 to GluN2A DNA (for the partial agonist studies, a total
amount of DNA of 8µg was used instead). Two 10cm dishes of cells were
transfected per smFRET experiment.
For the negative cooperativity studies, the amount of DNA transfected per
10cm plate of cells was as follows. For experiments measuring the GluN1 ABD, cells
were transfected with 1.25µg of GluN1*-ABD, 1.25µg of GluN1*-streptag and 7.5µg of
GluN2A*. For experiments measuring the GluN2A ABD, cells were transfected with
2.5µg of GluN1*- streptag and 7.5µg of GluN2A*-ABD. For experiments measuring
the GluN1 TMDs, cells were transfected with 2.5µg of GluN1*-TMD and 7.5µg of
GluN2A*. For experiments measuring the GluN2A TMDs, cells were transfected
with 2.5µg of GluN1*-streptag and 7.5µg of GluN2A*-TMD.
For the partial agonist studies, the amount of DNA transfected per 10cm
plate of cells was as follows. For GluN1 agonist-binding domain experiments, 1 µg
GluN1-ABD DNA, 1 µg GluN1-TS DNA, and 6 µg GluN2A DNA were transfected per
10 cm dish of cells. For GluN2A agonist-binding domain measurements, 2 µg
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GluN1-TS DNA and 6 µg GluN2A-ABD DNA were used per plate. For GluN1
transmembrane measurements, 2 µg GluN1-TMD DNA and 6 µg GluN2A DNA
were used. For GluN2A transmembrane domain measurements, 2 µg GluN1-TS
DNA and 6 µg GluN2A-TMD DNA were used. Finally, for the GluN2A aminoterminal domain measurements, 2 µg GluN1-TS DNA and 6 µg GluN2A-ATD DNA
were used.
After a four-hour period of transfection, the media in the two 10cm dishes
was replaced with DMEM AQ-Media (Sigma) supplemented with FBS and P/S as
described above and also supplemented with 30µM GluN1 antagonist DCKA
(Abcam, Cambridge, MA) and 300µM GluN2A antagonist APV (Abcam). The cells
were then incubated overnight. The next day, the cells were harvested and
centrifuged at 2350 rpm (1111 rcf) for three minutes at 23°C in an Eppendorf 5810R
centrifuge with an Eppendorf A-4-62 rotor. The cells were then washed in 3mL of
Extracellular Buffer (ECB) (135mM NaCl, 3mM KCl, 2mM CaCl2, 20mM glucose,
and 20mM HEPES, pH 7.5) three times. The cells were then labeled by premixing
Alexa 555-C2-maleimide (Invitrogen, Carlsbad, CA) and Alexa 647-C2-maleimide
(Invitrogen) and combining them with the cell suspension to bring the
concentration of Alexa 555 to 600nM and Alexa 647 to 2.4µM. The sample was
then wrapped in foil and rotated at room temperature for 30 minutes. The cells
were washed three times with ECB and resuspended in 2mL of Solubilization
Buffer (1% Lauryl Maltose Neopentyl Glycol (Anatrace, Maumee, OH), 2mM
Cholesteryl Hydrogen Succinate (MP Biomedicals, Solon, OH), and protease
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inhibitors from Pierce Protease Inhibitor Mini Tablets (ThermoFisher Scientific,
Waltham, MA) in 1X PBS). The sample was covered in foil and nutated at 4°C for
one hour. The sample was then transferred to an ultracentrifuge tube and spun for
one hour at 44,000 rpm (100,000 rcf) at 4°C in a Beckman Ultracentrifuge using a
TLA 100.3 rotor. The supernatant was collected and kept on ice until being used.
This sample preparation process was repeated for each day of smFRET data
acquisition.

smFRET Slide Preparation
Silicone templates (Grace Bio-Labs, Bend, OR) were cleaned via bath
sonication in methanol for 30 minutes and stored in methanol. 20mm x 20mm
microscope cover glasses (Globe Scientific, Paramus, NJ) were cleaned via bath
sonication in a 5% solution of Liquinox phosphate-free detergent (Fisher
Scientific) for 10 minutes followed by washing with molecular-biology-grade water
and additional bath sonication in acetone for 10 minutes. The slides were washed
again with water and incubated for five minutes in Tl-1 solution (4.3% NH4OH and
4.3% H2O2) at 70°C. The slides were then washed with water, dried with a gentle
nitrogen flow, and subjected to plasma cleaning in a Harrick Plasma PDC-32G
Plasma Cleaner. The slides were then aminosilanized by submersion in a 1:40
Vectabond (Vector Laboratories, Burlingame, CA) to acetone solution by volume.
The slides were then dried with a gentle nitrogen flow and stored under vacuum.
The day before each experiment, 50µL of overnight PEG solution (0.25% w/w 5
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kDa biotin-terminated PEG (NOF Corp., Tokyo, Japan) and 25% w/w 5 kDa mPEG
succinimidyl carbonate (Laysan Bio Inc., Arab, AL) in 10mM sodium bicarbonate
(Sigma-Aldrich)) was applied to an oblong area of each slide created with silicone
templates (Grace bio-Labs) and the slides were incubated overnight in the dark at
room temperature. The day of the experiment, the two PEG-treated slides were
washed with water and dried with a nitrogen flow. Then, 50µL of short-chain PEG
solution (25mM short-chain 333 Da MS(PEG)4 Methyl-PEG-NHS-Ester Reagent
(Thermo Scientific) in 0.1M sodium bicarbonate) was applied to each slide, and the
slides were incubated for two to three hours at room temperature. Next, the 3
slides were washed with water and dried with a nitrogen flow. The silicone
templates were removed and an adhesive Hybriwell chamber (Grace Bio-labs) was
applied to each slide. Two press fit tubing connectors (Fisher Scientific) were then
applied to the ports of each chamber, and 36µL of streptavidin solution (0.2mg/mL
Streptavidin (Invitrogen) in 1X Imaging Buffer (1mM nDodecyl-β-D-maltoside
(Chem-Impex Int’l Inc., Wood Dale, IL) and 0.2mM Cholesteryl Hydrogen
Succinate (MP Biomedicals) in 1X PBS)) was injected into each chamber and
allowed to incubate at room temperature for 10 minutes. The chambers were then
washed with PBS. The supernatant that was prepared in the smFRET Sample
Preparation section above was diluted anywhere from 1:2 to 1:5 in 1X Imaging
Buffer, and the diluted protein sample was applied to each slide. Then slides were
incubated with the sample for 20 minutes at 4°C, the chambers were washed with
reactive oxygen species (ROXS) scavenging solution (3.3% w/w glucose
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(SigmaAldrich), 3 units/mL pyranose oxidase (Sigma-Aldrich), 0.001% w/w
catalase (Sigma-Aldrich), 1 mM ascorbic acid (Sigma-Aldrich), and 1 mM methyl
viologen (Sigma-Aldrich), in 1X Imaging Buffer (described above), pH 7.5; plus
12µg/mL glycine oxidase (Biovision, Milpitas, CA) and/or 1mM glutamate and/or
1mM glycine and/or 1mM ACBC as needed to create the appropriate experimental
conditions), and the slides were imaged.

smFRET Data Collection and Analysis
Data was acquired using a PicoQuant MicroTime 200 Fluorescence Lifetime
Microscope. Pulsed interleaved excitation (PIE) was used with an 80MHz pulse
rate to excite the fluorophores using 532nm (LDH-D-TA-530; Picoquant, Berlin,
Germany) and 637nm (LDH-D-C-640; Picoquant) lasers. The slide was observed
through an oil-immersed 100x objective (100× 1.4 NA; Olympus, Tokyo, Japan) and
mounted on a scanning x-y-z piezo stage (P-733.2CD; Physik Instrumente,
Karlsruhe, Germany). Photons emitted from the sample traveled back through the
objective to two SPAD photodiodes (SPCM CD3516H; Excelitas technologies,
Waltham, MA) through 550 nm (FF01-582/64;AHF, Tübingen-Pfrondorf, Germany
/Semrock, Rochester, NY) and 650 nm (2XH690/70;AHF) emission filters. A
detailed protocol for smFRET data collection and analysis is provided in Litwin, et
al. (45). For liganded conditions 1mM glutamate, 1mM glycine, and/or 1mM ACBC
were used, and for apo conditions at the glycine site glycine oxidase was used to
remove contaminating glycine. The number of molecules included in the final
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analysis for each condition of the negative cooperativity studies (Chapter 3) is as
follows: GluN1 ABD APO = 33, GLY = 46, GLU = 38, GLY/GLU = 32; GluN2A ABD
APO = 31, GLY = 35, GLU = 32, GLY/GLU = 34; GluN1 ABD with GluN2A E427G
APO = 36, GLY = 31, GLU = 41, GLY/GLU = 30; GluN1 TMD GLY = 43, GLU = 33;
GluN2A TMD APO = 45, GLY = 32, GLU = 40, GLY/GLU = 80. The final numbers of
individual molecule FRET traces that were included in the analysis for the partial
agonist studies were as follows: GluN1 ABD ACBC = 52; GluN1 ABD ACBC/GLU =
59; GluN2A ABD ACBC = 52; GluN2A ABD ACBC/GLU = 49; GluN1 TMD ACBC =
50; GluN1 TMD ACBC/GLU = 77; GluN2A TMD ACBC = 63; GluN2A TMD
ACBC/GLU = 51; GluN2A ATD ACBC = 48; GluN2A ATD ACBC/GLU = 49; and
GluN2A ATD GLY/GLU = 52.
Using Matlab (MathWorks, Natick, MA), the data were subjected to wavelet
denoising. Denoising was not performed on the data obtained in the partial
agonist study. FRET efficiencies were calculated using the intensity of the acceptor
and the intensity of the donor. Corrections for both donor and acceptor intensity
were made to subtract background and crosstalk, as well as to correct for
differences in quantum yield and detector efficiency prior to calculating FRET
efficiency. The resulting efficiency traces were compiled into histograms showing
the relative occupancy of various FRET efficiencies. The histograms were fit to
Gaussian curves to reveal the underlying conformational states using Origin
software (OriginLab, Northampton, MA).
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Photo cross-linking
In order to perform the unnatural amino acid crosslinking at interface 1, an
amber stop codon (tag) was introduced at site 700 of GluN1 using site-directed
mutagenesis. The GluN1 700tag DNA and GluN2A WT DNA were
cotransfected into HEK293T cells along with DNA constructs encoding the
aminoacyl-tRNA synthetase p-benzoyl-L-phenylalanine tRNA synthetase (BZPRS)
and the tag-codon-compatible tRNA. The unnatural amino acid BZP was included
in the media during and after transfection at a concentration of 1mM. These DNA
constructs were transfected at a ratio of 10:3:2:10 µg GluN1:GluN2A:BZPRS:tRNA.
Crosslinking between the subunits of the BZP-containing NMDA receptor was
induced via exposure of receptors to UV light. The transfected cells were washed
with PBS and exposed to UV light of wavelength 254 nm using a Stratalinker 1800
at an intensity of 3mM/cm2 for 3-15 minutes on ice. Crosslinking was carried out in
the presence of 100 µM glutamate and glycine and 5 mM MgCl2. SDS-PAGE was
performed on the receptors to validate the inter-subunit crosslink. Anti-GluN1
antibody ab134308 (abcam) and anti-GluN2A antibody ab240884 (abcam) were
used to probe for GluN1 and GluN2A, respectively and observe the shift in
molecular weight associated with the formation of the GluN1/GluN2A crosslinked
dimer.

Electrophysiology
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HEK 293T cells at 40–50% confluency in 35mm dishes were transfected
using Lipofectamine 2000 (Invitrogen) and co-transfected with GFP. 300 µM APV
and 30 µM DCKA were present in the medium during and after transfection.
Whole-cell patch clamp recordings were performed 24 hours after transfection
using fire-polished borosilicate glass pipettes (Sutter instruments, Novato, CA)
with 3-5 Mega ohms resistance and filled with internal solution (135mM CsF,
33mM CsOH, 2mM MgCl2, 1mM CaCl2, 11mM EGTA, 10mM HEPES, adjusted to pH
7.4 with CsOH). The external solution (140mM NaCl, 2.8mM KCl, 1mM CaCl2,
10mM HEPES, adjusted to pH 7.4 with NaOH) was (with and without 1mM
glutamate or 1mM glycine or 1mM ACBC) applied to lifted cells using a stepper
motor system (SF-77B, Warner Instruments, Hamden, CT) with triple barrel
tubing. Recordings were performed using an Axopatch 200B amplifier (Molecular
Devices, San Jose, CA) at −60 mV hold potential, acquired at 10 kHz using
pCLAMP10 software (Molecular Devices), and filtered online at 5 kHz. Outside out
patch recordings were performed 24-48 hours post transfection using the same
pipettes, solution composition, and amplifier (but with 50 kHz acquisition and 10
kHz filtering). Patches were positioned in front of a custom-built triple barrel
perfusion tool (168), and solution exchange times using open tip currents were
routinely measured at the end of each experiment (200-400 µs). Data from either
deactivation decays or dissociation decays were fit to a double exponential decay
with a fixed zero offset. Patches were individually fit and the results averaged to
provide the reported weighted time constants.
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Homology Modeling and Molecular Dynamics Simulations
In order to perform the Molecular Dynamics simulations on interface 1, a
homology model for the dimer of a heteromeric GluN1/GluN2A NMDA receptor
(Figure 9 Ia) was built by using MODELLER (169) software. The template structure
chosen for modeling was the crystal structure of the Rattus norvegicus
GluN1/GluN2B NMDA receptor (PDB: 4PE5 (16)). The Rattus norvegicus GluN2A
sequence was used to prepare the homology model and exhibited ~72% sequence
identity with GluN2B. The Rattus norvegicus sequences can be accessed in the
UniProt Database with UniProt Id P35439 for GluN1, Q00959 for GluN2A, and
Q00960 for GluN2B. In order to perform the Molecular Dynamics simulations on
interface 2 (Figure 9 IIa), structures for the isolated agonist-binding domain dimer
of GluN1/GluN2A were selected as the starting points. The structure PDB 5I57
(165) was chosen as the starting point for the glutamate-glycine bound condition
and the glutamate-only bound condition. For the glycine-only bound condition
PDB 4NF5 (157) was used, and for the no ligand bound condition PDB 4NF4 (157)
was used. For the partial agonist simulations, MODELLER software (169) was used
for building the homology model of the GluN1/GluN2A NMDA receptor bound to
glutamate and ACBC by taking template structures deposited at the protein data
bank (PDB: 4PE5, 1Y1Z, 4NF5 (16, 40, 157). The structure models for simulation
represented interface I (inter-dimer interface) and interface II (intra-dimer
interface).
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For all simulations, ten model structures were prepared, and the structure
with the lowest Discrete Optimized Protein Energy (DOPE) score was utilized in
the simulations. Missing residues and hydrogen atoms were added to the structure
using the psfgen (170) module of the Visual Molecular Dynamics software (VMD)
(171). For the simulations in Chapter 3 of Interface 1, the structure was then placed
at the center of a 113x124x136 Å box containing 17-19 charge-neutralizing sodium
ions and ~55190 TIP3P water molecules. The total number of atoms for the
simulations of interface 1 ranged from 186639-186666. For the simulations of
Interface 2, the structure was placed at the center of a 60x68x75 Å box containing
6-9 charge neutralizing chloride ions and 21532-23141 TIP3P water molecules. The
total number of atoms for the simulations of interface 2 ranged from 73301-78323.
For the simulations in Chapter 4, the model of the inter-dimer interface was
placed at the center of a 96 × 101 × 122 Å box consisting of 17-18 charge-neutralizing
sodium ions, ∼55197 TIP3 water molecules, and a total number of atoms of 186670.
For the model representing the intra-dimer interface, the structure was placed at
the center of a 91 × 89 × 104 Å box consisting of 7-8 charge-neutralizing chloride
ions, ∼23139 TIP3 water molecules, and a total number of atoms of 78330.
Each system was energy-minimized using 5000 steps of conjugate gradient
energy minimization applying a restraint force of spring constant 4kcal/mol/Å2 on
the backbone atoms as well as on the sidechain heavy atoms of residues directly
interacting with the ligands. This was followed by a 5 ns equilibration simulation
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using a 1 fs time step while progressively decreasing the restraint force constant to
zero.
Subsequent production runs were conducted using a time step of 2 fs under
a constant number of particles (N), pressure (P=1bar), and temperature (T=310K)
ensemble, with pressure controlled by the Nose-Hoover Langevin piston and
temperature by the Langevin thermostat. Periodic boundary conditions were used.
Long-range electrostatic interactions were calculated by the Particle Mesh Ewald
(PME) method (172), with covalent bonds involving hydrogen atoms restrained by
SHAKE. Short-range non-bonded interactions were smoothly switched off between
10 Å and 12 Å with a 14 Å cutoff used for pair list updates. The simulations were
conducted using the program NAMD 2.12 (173) and the CHARMM36 force field
(174) for the NMDA receptor with the application of the cMAP dihedral correction
and the CHARMM general force field (CGENFF) (175) for the ligands. Analysis was
conducted using Tcl scripts and VMD (171).
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Chapter 6: Discussion and Future Directions
At the start of this thesis work, I began by outlining two specific aims for
my research: to characterize the allosteric communication between the glutamateand glycine-binding subunits in the NMDA receptor and to determine the
mechanism of partial agonism in the NMDA receptor. I have successfully
completed both of those aims with the work presented above in this dissertation.
In the course of completing my thesis work, I have composed a review article
concerning the use of smFRET to study various systems involved in glutamate
signaling (56), studied the inter-subunit allosteric communication within the
NMDA receptor (53), and investigated the effects of a partial agonist on the
conformational landscape of the NMDA receptor. The work has served to increase
the understanding of the dynamic motions of the NMDA receptor and to show
how those motions control various aspects of NMDA receptor function.

Investigations of NMDA Receptor Negative Cooperativity
In my studies of the allosteric communication between the subunits of the
NMDA receptor, I began by investigating the conformational landscape and the
transitions between conformational states of the receptor’s agonist-binding
domains. During the course of these investigations, I observed that the binding of
an agonist to its respective agonist-binding domain led to a narrower distribution
of conformational states and also led to a reduction in the frequency of transitions
between those conformational states. This change occurred for both the glycine136

binding domain and the glutamate-binding domain of the receptor. This
observation indicates that a given NMDA receptor agonist tends to cause its
agonist-binding domain to be closed and relatively stable in conformation. In
addition, I observed that the binding of agonist to one agonist-binding domain
caused the other agonist-binding domain to adopt a more broad distribution of
conformational states and to increase the frequency of transitions between states.
Again, this observation held true regardless of which agonist-binding domain was
being measured. This indicates that the binding of agonist to the adjacent domain
leads the agonist-binding domain to become less stable and more dynamic. I
therefore propose that, in this way, the binding of agonist to one site on the
receptor leads to a reduction in the affinity for agonist at the other site. These
observations provide important insight into the mechanism by which protein
dynamics affect the phenomenon of negative cooperativity within the NMDA
receptor.
Due to the reporting of a mutant NMDA receptor that does not exhibit
negative cooperativity (32), I was able to take these investigations of NMDA
receptor negative cooperativity even farther by measuring the conformational
landscape of this mutant receptor. In the wild-type receptor, the binding of agonist
led to an increase in low-FRET states in the adjacent domain. It was these lowFRET states that our group therefore hypothesized were responsible for mediating
the negative cooperativity. When I made smFRET measurements of the mutant
receptor, I observed that the low-FRET states were absent. I was, therefore, able to
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confirm that the low-FRET states that are exhibited in the presence of a co-agonist
are responsible for mediating the negative cooperativity between subunits.
This observation is particularly important because it highlights one of the
major strengths of the smFRET technique: the ability to observe individual
conformational states of the receptor and their relative occurrence under various
conditions. It is easy to see how studies just like this one could identify specific
conformational states of a protein of interest that are different between the wildtype species and a disease-causing mutant. Being able to clearly identify specific
conformational states within a protein of interest that mediate a particular disease
would provide a target for drug discovery research that could modulate the
aberrant conformational states back to their wild-type levels. Furthermore, this
strategy can be utilized to target only the disease-causing conformations of the
protein, thereby preserving the physiologically-necessary activity of the protein.
Overall, the smFRET technique offers a powerful method for determining
conformational changes in macromolecules with a high degree of conformational
resolution.
In addition studying the conformational landscape of the agonist-binding
domains of the NMDA receptor, I also conducted measurements of the receptor’s
transmembrane domains. With these measurements, I was able to observe the
conformational landscape in the presence of full agonists of the receptor. These
studies showed that the transmembrane region only shifts into low-FRET states
when in the presence of both co-agonists. The transmembrane region of the
138

NMDA receptor is very structurally similar to the Na/K channels (159, 160), the
open- and closed-channel structures of which have been resolved. When the
structures of the Na/K channels in the open and closed states are compared to the
conformational states of the NMDA receptor transmembrane domain are
compared, it is the case that the high-FRET states correspond to a closed
conformation while the low-FRET states correspond to an open conformation. For
this reason, we propose that the low-FRET states that are only present with both
co-agonists present represent the open channel conformational states of the
receptor.
In addition, observations of the rate of transitions between states indicated
a significant increase in conformational transitions in the presence of both
agonists as compared to in the presence of only one agonist. These observations
indicate that the smFRET measurements are accurately recapitulating the
functional observations that the ion channel pore that is formed by the
transmembrane domains needs to open when both agonists are present and only
when both agonists are present.

Insights into the Mechanism of Partial Agonism in the NMDA Receptor
In addition to performing studies of the negative cooperativity in the
NMDA receptor, I also conducted studies of the mechanism of partial agonism in
the receptor. For these studies, I utilized 1-Aminocyclobutanecarboxylic acid
(ACBC), a glycine-site partial agonist that activates the receptor to 13% of the
139

response elicited by full agonists (38). Through observations of the conformational
landscape of the agonist-binding domains of the receptor in the presence of ACBC,
we saw that the partial agonist enhances the ability of the subunits to allosterically
communicate with each other. The GluN1 domain favored a more open
conformation in the presence of ACBC with glutamate versus in the presence of
glycine with glutamate. This indicates that the partial agonist enhances the ability
of glutamate to cause the GluN1 agonist-binding domain to open. Furthermore,
the GluN2A domain also favored a more open conformation in the presence of
ACBC with glutamate versus in the presence of glycine with glutamate. This
indicates that the ability of the GluN1 agonist to cause the GluN2A domain to open
is enhanced with partial agonist as compared to with full agonist. These results
indicate that the allosteric communication between the GluN1 and GluN2A
subunits is enhanced in both the GluN1 to GluN2A direction and vice-versa.
This result indicating that the partial agonist enhanced the allosteric
communication between subunits was unexpected. At the outset of the study, I
hypothesized that an agonist that partially activates the receptor would exhibit a
conformational landscape that was intermediate between that of the receptor in
the absence of any agonist and that of the receptor in the presence of full agonist.
Instead, we observed a conformational landscape that went beyond that of the fullagonist-bound receptor. In addition to the smFRET measurements of the agonistbinding domains, we also investigated the rate of glutamate dissociation form the
NMDA receptor in the presence of full vs partial agonist at the glycine site through
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the use of electrophysiology. We observed that glutamate dissociates from the
receptor faster in the presence of partial agonist versus in the presence of full
agonist at the GluN1 subunit. This result aligns well with the observation that the
glutamate-binding domain favors an open cleft conformation in the presence of
ACBC more so than in the presence of glycine. Taken together, these observations
indicate the mechanism of partial agonism in the receptor; the partial agonist at
the GluN1 agonist binding site causes an enhancement of the negative allosteric
communication between the subunits which results in an open glutamate-binding
cleft that favors glutamate dissociation.

Glycine-Dependent Desensitization and Physiological Relevance of
Negative Cooperativity
In the continued presence of agonists, the NMDA receptor undergoes
desensitization via a variety of mechanisms including calcium-dependent
desensitization, glycine-independent desensitization, and glycine-dependent
desensitization (3). In glycine-dependent desensitization, the NMDA receptor
exhibits a rapid reduction in current following an initial current peak when it is
equilibrated in a low concentration of glycine and then exposed to a glutamate
pulse (176). Importantly, the rapid desensitization from the initial peak current is
reduced as the surrounding concentration of glycine is increased and is ultimately
eliminated once the concentration of glycine reaches a high level. It is understood
now that this glycine-dependent desensitization is caused by a reduction in NMDA
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receptor affinity for glycine upon binding of glutamate via negative cooperativity
(32, 156, 177). The rapid decay of current upon glutamate application is caused by
the unbinding of glycine from receptors that suddenly have a reduced affinity for
glycine. Increasing the glycine concentration eliminates this desensitization
because the increased glycine concentration overcomes the effect of the reduced
affinity and allows glycine to remain bound to the NMDA receptor molecules even
when glutamate is also bound.
It has been shown that synaptic glycine concentrations vary by brain region
and are controlled by glycine transporters. In some regions, the glycine
concentration is sufficient to saturate the glycine-binding site of the NMDA
receptor, while in other regions the concentration of glycine is at a sub-saturating
level (178-182). In addition, NMDA receptor-evoked currents exhibit a long time
scale (100s of milliseconds (183)) which would allow time for glycine-dependent
desensitization to occur under physiological conditions (37). It is possible,
therefore, that glycine-dependent desensitization could occur under physiological
conditions in synapses that possess a sufficiently low concentration of glycine.
The physiological relevance of NMDA receptor negative cooperativity and
glycine-dependent desensitization is not yet fully understood, but the
phenomenon of glycine-dependent desensitization could serve an important role
in controlling the shape, length, or timing of NMDA receptor-evoked excitatory
post-synaptic currents (EPSCs). Glycine-dependent desensitization could serve to
modulate the shape of NMDA receptor EPSCs by causing a rapid reduction in
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current immediately following an initial current peak. Additionally, the time
course of NMDA receptor EPSCs could be altered through the regulation of
desensitization. Finally, desensitization could lead to the existence of a fraction of
receptors that undergo a refractory period that prevents them from being ready to
activate at the next instance of neurotransmitter release in the synapse (184, 185).
The above modulations of NMDA receptor EPSCs could be controlled on a
synapse-to-synapse level by controlling the glycine concentration of the synapse. It
is possible that the glycine concentration is relatively stable at either a saturating
or sub-saturating level at each synapse, which would result in only a certain
fraction of synapses exhibiting glycine-dependent desensitization. Alternatively,
glycine concentration at each synapse could be controlled by modulating glycine
release and reuptake over time to result in a synapse that would exhibit glycinedependent desensitization only under certain conditions. This process could serve
as an additional way that NMDA-receptor EPSCs are regulated in the human
central nervous system.

Future Directions for Understanding the NMDA Receptor StructureFunction Relationship
There are a number of investigations that could be undertaken to further
the thesis work presented herein. Perhaps the most obvious next step to this work
is to make measurements of the conformational landscape of the NMDA receptor
in the presence of glutamate-site partial agonists. This would complement the
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studies already performed with ACBC, a glycine-site partial agonist. Conducting
these studies would provide interesting insights into whether the GluN2A partial
agonists cause an increase in the allosteric communication between the subunits
of the receptor in the same way as the GluN1 partial agonist does. Alternatively, it
is possible that the glycine-site and glutamate-site partial agonists work to alter
agonist efficacy through completely different mechanisms. If this is the case, it
becomes even more important to study how these mechanisms differ so that we
can gain a complete picture of how NMDA receptor activation is controlled at the
level of the agonist-binding domains.
Another direction future studies could take in the area of studying the
mechanism of partial agonism in the NMDA receptor would be to study additional
GluN1 partial agonists. During my studies, I have investigated the effects of
glycine, which activates the receptor to a 100% response, and ACBC, which
activates the receptor to only 13% of a maximal response. A useful investigation
would be to perform the same investigation using partial agonists of the GluN1
subunit that activate the receptor between 13% and 100% to see if there is a gradual
shift in the conformational landscape between agonists that activate the receptor
very little and agonists that fully activate the receptor. A partial agonist such as
ACPC or L-Alanine, which both activate the receptor to 79% (3), could be used for
such studies. I expect that these studies would show that as the agonist approaches
100% efficacy, the conformational landscape elicited by that agonist approaches
that elicited by the full agonist glycine. An agonist that activates that receptor
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above the typical 100% level (such as tri-F-DL-Alanine, which activates the receptor
to 130%) could also be informative in the process of understanding the relationship
between conformational landscape and agonist efficacy. Based on my observations
of the conformational landscape in the presence of partial agonists, I would expect
a super-agonist to reduce, rather than enhance, the degree of negative allosteric
communication within the NMDA receptor. These same types of studies could
then also be carried out for GluN2A partial agonists and super-agonists to gain an
understanding of the similarities and differences between the mechanism of
partial agonism in the two NMDA receptor subunits.
In addition to performing the same sort of investigations using additional
agonists of varying efficacy, entirely new types of measurements could be used to
gain additional understanding of the NMDA receptor conformational landscape
and its relationship to NMDA receptor function. One such measurement
technique is to utilize multi-color FRET. In a FRET measurement with two
fluorophores, there is a single measurement of the FRET efficiency between those
two fluorophores. In a measurement consisting of three independent fluorophores,
however, there are three separate distances being measured simultaneously. When
the number of fluorophores is increased to four, the number of inter-fluorophore
distances that can be observed is increased to six. Alternatively, in a sufficiently
large molecule such as the NMDA receptor, two independent pairs of FRETing
fluorophores can be observed. The ability to observe the motions of two different
regions of the receptor opens up a large number of possibilities to answer
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questions concerning the correlation of conformational states at different regions
of the NMDA receptor. For example, which conformational states of the agonistbinding domains are correlated with the open-channel state of the transmembrane
domain? Does the opening or closing of one agonist-binding domain affect the
conformation of the other agonist-binding domain of the receptor? How does the
amino-terminal region of the receptor change conformation during receptor
activation and desensitization? These and many other questions could be
addressed through the use of four-color FRET monitoring two independent FRET
pairs within the same molecule.
The challenges associated with achieving four-color FRET measurements in
a single protein molecule are numerous. The most significant challenge is that of
achieving reliable and site-specific labeling with four different fluorophores.
Fortunately, in the case of two independent FRET pairs within the same molecule,
one does not need to know the position of all four fluorophores, only the position
of each pair of fluorophores; knowing that the first donor/acceptor pair is on a
specific domain of the receptor while the second donor/acceptor pair is on a
different domain will allow the observer to assign the FRET efficiency
measurements to those respective domains with specificity. In order to achieve
this fluorophore labeling strategy, two separate attachment chemistries are
needed, one for FRET pair one and another for FRET pair two. For two-color FRET,
cysteine residues are typically used to attach the FRET pair. This attachment
chemistry would be utilized for FRET pair one. For the second attachment scheme,
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unnatural amino acids or the SNAP-tag could be used to attach the fluorophores.
Optimizing labeling conditions that result in the efficient labeling of all four sites
will prove to be the most difficult hurdle in designing four-color FRET
measurements.
After the biological hurdle of single-molecule labeling has been overcome,
the difficulties of data acquisition and analysis must be addressed. A system
capable of observing all four different fluorophores of interest must be used. This
system must be able to excite the donor fluorophores, observe the resulting donor
and acceptor intensities, and separate out the four different emission signals from
the fluorophores while minimizing crosstalk and signal loss. After acquiring the
data, it must be corrected for factors such as cross-talk, background signal, direct
acceptor excitation, and detector efficiency. After this the calculation of FRET
efficiency and subsequent identification of correlated conformational states is
fairly straightforward. As mentioned previously, this capability would allow many
important questions about the NMDA receptor and many other molecules of
interest to be answered. With its incredible power to resolve conformational
correlations within individual molecules, application of four-color FRET to explore
the conformational landscape of the NMDA receptor will serve as the natural next
step of this thesis project.
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